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Summary 
 
As cultured embryonic stem (ES) cells can be differentiated in neurons under well-
defined conditions, they provide a unique opportunity to model and study diseases of the 
nervous system such as Rett syndrome. Most cases of this tragic neurodevelopmental 
disorder affecting about 1 young girl in 10’000 are caused by mutations in MECP2, a 
gene encoding the methyl-CpG-binding protein 2. Despite the generation of very useful 
mouse models recapitulating some important features of Rett syndrome, like the lack of 
normal brain growth, breathing arrhythmia and movement deficits, the function of 
MeCP2 in the brain remains unclear at this point. A few years ago, our laboratory 
established a differentiation procedure allowing the generation of virtually pure 
progenitors defined as Pax6-positive radial glial cells. As they do in vivo, these cells go 
on to generate glutamatergic neurons. One key characteristic of this system is that 
essentially all cells differentiate synchronously and I used it during the course of my PhD 
thesis to compare wild-type ES cells with ES cells lacking MeCP2. During the transition 
from progenitors to neurons, the size of nuclei increases by about 40% within a period of 
about 10 days, while nuclei of neurons lacking MeCP2 fail to grow at the same rate. Both 
the acute re-expression of MeCP2 in MeCP2 Stop-Floxed neurons following the excision 
of a stop cassette using Cre, as well as the viral delivery of MeCP2 to null neurons were 
found to rescue the small nuclear size phenotype. In an effort to correlate the size of the 
nuclei with their transcriptional activity, I compared the rate of total in vitro RNA 
transcription in pure nuclei isolated from wild-type vs. Mecp2 -/y (null) and Mecp2 Stop-
Floxed ES cell-derived neurons. Regardless of the type of MeCP2 mutation, the neuronal 
nuclei lacking MeCP2 were found to be significantly less transcriptionally active 
compared to the wild-type nuclei. These results suggest that MeCP2 may have a general, 
genome-wide role in regulating the rate of RNA transcription, including ribosomal RNA 
that represents the major species investigated in such experiments. As BDNF levels have 
been reported to be reduced in the brain of Mecp2 -/y mice, I also examined if ES cell-
derived neuron lacking MeCP2 would reflect this potentially important aspect of the 
disease, since decreased levels of BDNF could be hoped to be corrected and to improve 
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the patients’ condition. At about 15 days in vitro, the levels of BDNF were found to be 
reduced by about 30% and the acute expression of MeCP2 was found to restore the 
expression of BDNF to levels similar to those seen in wild-type neurons.  
In the second part of my work, I found that the sphingosine-1 phosphate analogue 
fingolimod (FTY720), recently introduced as the first oral treatment of multiple sclerosis, 
increases BDNF levels both in wild-type and Mecp2 -/y ES cell-derived neurons by 
mechanisms involving MAPK signaling and neuronal activity. In MeCP2 mutant mice, 
FTY720 increases BDNF levels in the striatum as well its volume, ameliorates locomotor 
activity and extends the lifespan by 50%.  
As microcephaly is one of major symptoms of Rett syndrome, I also investigated in the 
third part of my PhD work the effects of the lack of MeCP2 on cell proliferation. While 
MeCP2-deficient ES cells do not have a proliferation defect, neuronal progenitors lacking 
MeCP2 generate fewer neurons compared with wild-type cells. This difference between 
ES cells and neuronal progenitors may result from the fact that the levels of MeCP2 
expression are much higher in neurons and neuronal progenitors compared to ES cells. 
Taken together, my results show that an ES cell based system represent a useful tool to 
understand molecular mechanisms underlying human neurological disorders.  
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1. Introduction 
 
“Men ought to know that from the brain, and from the brain only, arise our pleasures, 
joys, laughter and jests, as well as our sorrows, pains, grief and tears. It is the same thing 
which makes us mad or delirious, inspires us with dread or fear, whether by night or by 
day, brings sleeplessness, inopportune mistakes, aimless anxieties, absent-mindedness, 
and acts that are contrary to habit”. Hippocrates 460-377 BC 
 
The brain is the most complex and fascinating organ in the human body. Together with 
the spinal cord and the peripheral nervous system, it directs the function of all other 
organs. Not only can it process and interpret sensory signals, but it also can store 
information for long periods of time. Defects in neural development can lead to severe 
problems, including for example a relatively frequent condition designated autism. While 
autism is a complex disease likely to have more than just one genetic explanation, one 
condition, Rett syndrome, appears to be experimentally approachable. It is a devastating 
neurodevelopmental disorder mainly affecting young girls, all of them having autistic 
traits. Essentially all cases of Rett syndrome are caused by mutations in the X-linked gene 
MECP2. The affected girls have a short period of apparently normal development but 
after 6 to 18 months they go through a period of developmental stagnation accompanied 
by neurological symptoms ranging from seizure to breathing arrhythmia, mental 
retardation, microcephaly and autism. Unlike many other neurological disorders, very 
useful mouse models exist for the Rett syndrome, mainly due to the monogenic nature of 
the disease and the fact that MECP2 is located on the X chromosome in both mouse and 
human. In spite of this, the role of MeCP2 in brain function is still very unclear at this 
point. The aim of my work was to try and improve our understanding of the role of 
MeCP2 in developing neurons using a novel cell culture system.  
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1.1. Rett syndrome 
 
In 1954, Dr. Andreas Rett, a pediatrician and neurologist in Vienna, Austria, and his 
nurse first noticed two girls as they sat in his waiting room with their mothers. They 
observed these children making the same repetitive hand-washing motions. Dr. Rett then 
compared their clinical and developmental histories and discovered they were very 
similar. This coincidental occurrence prompted Dr. Rett to search for more patients with 
the same unusual behavior. In 1966, Dr. Rett described similar findings in 22 patients, 
reporting for the first time a unique clinical entity that now bears his name (Rett, 1966). 
But it would not be until 17 years later that Rett syndrome (RTT) became recognized in 
the medical community when Dr. Bengt Hagberg, a Swedish neurologist, and his 
colleagues reported 35 cases of RTT in the English language (Hagberg et al., 1983), and 
recognized this clinical entity as a condition ‘‘similar to a virtually overlooked syndrome 
described by Rett in the German literature.’’ 
 
Rett syndrome is a postnatal progressive neurodevelopmental disorder affecting ~1 in 
10’000 females (Rett, 1966). The affected girls develop normally until 6-18 months, 
achieving the appropriate milestone, such as ability to walk and some times even 
speaking a few words. However, there is considerable variability in the severity of the 
symptoms (see below). The brief period of developmental progress is followed by 
stagnation distinguished by growth arrest and microcephaly. After this, patients go 
through a rapid regression phase. The previously acquired skills are lost and a variety of 
symptoms develop including mental retardation, autistic features, breathing arrhythmia, 
loss of motor coordination, seizure, loss of purposeful hand use and development of 
stereotypic hand movements instead (Figure 1.1) (Chahrour and Zoghbi, 2007). Kerr and 
colleagues found an annual mortality rate in Rett syndrome of 1.2% (Kerr et al., 1997). 
Autopsy studies show a 12%–34% reduction in brain weight and volume in patients with 
RTT (Jellinger et al., 1988) with a reduction in the neuronal size in the cortex, thalamus, 
basal ganglia, amygdala, and hippocampus. In addition, an increase in neuronal cell 
packing in the hippocampus is reported (Kaufmann and Moser, 2000). 
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Figure 1-1 Onset and progression of RTT clinical phenotypes (adapted from Chahrour and Zoghbi, 
2007) 
 
Given that the vast majority of patients with RTT are females, early studies postulated an 
X-linked dominant mode of inheritance. In 1999, the group of Dr. Huda Zoghbi found 
that the gene methyl-CpG-binding protein 2 (MECP2), located in Xq28, was mutated in 
more than 95% cases of classical Rett syndrome (Amir et al., 1999).  
 
More than 99% of RTT cases are sporadic. Most of the mutations in MECP2 arise de 
novo in paternal germline, thus explaining the sporadic nature of RTT and its occurrence 
predominantly in girls (Chahrour and Zoghbi, 2007, Trappe et al., 2001). 
 
Mutations affecting the nuclear localization (NLS) of MeCP2 or early truncating 
mutations tend to cause more severe phenotypes than missense mutations, whereas C-
terminal deletions are associated with milder phenotypes (Naidu et al., 2003, Smeets et 
al., 2005).  
 
A major source of the phenotypic variability associated with different MECP2 mutations 
in females is the pattern of X chromosome inactivation (XCI) (Chahrour and Zoghbi, 
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2007). In females, only one of the two X chromosomes is active in each cell. The inactive 
X chromosome is silenced by packaging into transcriptionally inactive heterochromatin 
(Chow et al., 2005). X-inactivation occurs so that the female, with two X chromosomes, 
does not have twice as many X chromosome gene products as the male, which only 
possess a single copy of the X chromosome. The XCI is thought to be a random process 
occurring during gastrulation (Okamoto et al., 2004), such that roughly half of the cells 
have the maternal X chromosome active and the other half have the paternal X 
chromosome active. In male mutants, with only one X chromosome, all the cells express 
the mutant allele which may often be lethal. However, a female with a MECP2 mutation 
is typically mosaic, whereby part of her cells express the mutant MECP2 allele while the 
others express the wild-type MECP2 allele. In some extreme cases, most of the cells 
inactivate the mutant X chromosome, so that some patients may be only mildly affected 
or are even asymptomatic carriers of MECP2 mutations. The latter cases are usually 
identified because of the occurrence of RTT in their offspring (Dayer et al., 2007) and 
some have probably been misdiagnosed as being autistic patients.  
 
 
 
1.2. MeCP2 function 
 
MeCP2 is a protein that binds to the methylated DNA, in vitro and in vivo (Skene et al., 
2010). It has been known for many years that cytosine in the sequence CpG is frequently 
methylated in the vertebrate genome by DNA methyltransferase (Bestor et al., 1988). 
Some areas of genome are methylated more heavily than others and the highly 
methylated areas tend to be less transcriptionally active through mechanisms not fully 
understood. DNA methylation is then generally thought to act as a landmark for 
transcriptional suppression. However, DNA methylation per se can not convey any 
message and it is believed that methylation of DNA attracts binding of proteins that 
interpret the methylation (Bird and Wolffe, 1999). 
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MeCP2 was identified in a screen to find proteins that bind specifically to methylated and 
not non-methylated DNA probes (Lewis et al., 1992). MeCP2 binds to one symmetric 
methyl-CpG pair through its methyl-binding domain (MBD) (Meehan et al., 1992). 
MeCP2 was then initially thought to function as a global transcriptional repressor (Nan et 
al., 1997). However, transcriptional profiling of MECP2 knock-out mice revealed rather 
subtle, but consistent, down-regulation in the expression of many genes in the brain 
(Chahrour et al., 2008). If MeCP2 were a general transcriptional repressor, one would 
expect instead increased expression of many genes in its absence. How MeCP2 affects 
the transcription of genes relevant to brain development remains unclear at this point. 
 
 
 
1.3. RTT animal models 
 
Like in humans, the mouse MECP2 gene is located on the X chromosome. Shortly after 
the discovery of the genetic basis of Rett syndrome, mouse lines were generated, by 
targeting of the MECP2 gene, in the hope of mimicking relevant aspects of human RTT 
(Chen et al., 2001, Guy et al., 2001). 
 
Heterozygous female mutants (MECP2 +/–) seem normal for the first three to four 
months, but begin to show symptoms such as weight gain, reduced activity and ataxic 
gait (Chen et al., 2001, Guy et al., 2001). At a later age, they frequently displayed tremor, 
heavy breathing and cold extremities indicating autonomic abnormalities that are also 
characteristics of human patients.  
 
In male animals, removal of MECP2 leads to generation of a null mutant (MECP2 -/y). 
While the animals are viable at birth, they show symptoms around weaning. They 
develop a stiff, uncoordinated gait and reduced spontaneous movement between three and 
eight weeks of age. Most animals develop hind-limb clasping and irregular breathing and 
subsequently die at around postnatal day 54 (Guy et al., 2001). Brains of MECP2-null 
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mice are significantly smaller than wild-types, with an increase in cell packing density 
and reduction in neuronal and neuronal nuclei size (Chen et al., 2001). The smaller brain 
and the general reduction of neuronal cell size in the MECP2-deficient mice are 
consistent with what has been described in human RTT patients.  
 
Strikingly, the group of Adrian Bird showed that re-expression of MeCP2 from its 
endogenous promoter, even in severely symptomatic mice, leads to a robust reversal of 
the phenotypes (Guy et al., 2007). While this experiment does not suggest an immediate 
therapeutic approach to RTT, it establishes the principle of reversibility in this mouse 
model. This observation is almost unique in the field of disease modeling and raises 
hopes that the lack of MeCP2 does not lead to irreversible changes in the developing 
brain, such as death of large number of neurons for example. This striking observation is 
somewhat reminiscent of previous results obtained by the group of René Hen and 
colleagues indicating that huntingtin aggregates disappear, as do the behavioral anomalies, 
when the production of the mutant protein is discontinued in transgenic mice (Yamamoto 
et al., 2000) 
 
Currently, the search for therapeutic approaches relies mostly on the lessons learned from 
the mouse model. One of the genes whose expression appears to be affected in the brains 
of MECP2 mutant mice is increasingly regarded as an “endogenous neuroprotectant”, 
brain-derived neurotrophic factor (BDNF) (Chang et al., 2006, Tremblay et al., 1999). 
Chang and colleagues also showed that BDNF expression levels can greatly affect the 
disease progression in the MeCP2 mutant mice. Over-expression and down-regulation of 
BDNF in forebrain of MECP2 null mice were shown to improve and worsen the 
symptoms, respectively (Chang et al., 2006). These results suggest that BDNF and the 
up-regulation of its expression may be a useful avenue to follow to develop new 
approaches to treat Rett syndrome. 
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1.4. ES cell-derived neurons 
 
MeCP2 is highly expressed not only in brain but also in lung, heart and kidney 
(Shahbazian et al., 2002a). Work with mouse models of RTT suggests that the main cell 
type affected in the Rett syndrome are neurons, as specific removal of MeCP2 in neurons 
of forebrain results in Rett-like phenotype in mice (Chen et al., 2001). In addition, re-
expression of MeCP2 only in post-mitotic neuron rescued the Rett syndrome in mice 
(Luikenhuis et al., 2004). Recently, it was shown that in adult mice brains, the levels of 
MeCP2 are about six times higher in neuronal nuclei, compared with glial nuclei (Skene 
et al., 2010). These data suggest an important role for MeCP2 in neurons compared to 
glia. Therefore, it would be useful to learn more about the function of MeCP2 in neurons. 
However, this remains a challenging objective with traditional systems such as brain or 
tissues culture lysates given their cellular heterogeneity and the difficulties in following 
defined cell population over time. To circumvent these difficulties, I used mouse 
embryonic stem (ES) cells. Under suitable tissue culture conditions, ES cell can usefully 
recapitulate early events in neurogenesis (Bibel et al., 2004, Nikoletopoulou et al., 2007). 
As wild-type or genetically modified ES cells can be grown in unlimited quantities, their 
differentiation into neurons represents an attractive model for studying the function of 
genes involved in neurological disorders, such as Rett syndrome. A few years ago, our 
laboratory established a robust differentiation protocol (Bibel et al., 2007, Bibel et al., 
2004) leading to the generation of well-defined and virtually pure populations of Pax6-
positive radial glial (RG) cells with a profile and developmental potential characteristic of 
Pax6-positive RG cells of the cortex. Like their in vivo counterparts, these progenitors 
generate homogeneous populations of glutamatergic neurons (>95%). 
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1.5. Aim of this thesis 
 
The aim of this thesis was to increase our understanding of the Rett syndrome at the 
cellular and molecular levels using a novel cellular assay. I also attempted to use the 
knowledge derived from these experiments to begin to address the disease and possible 
treatments at the organism level. 
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2. Materials and Methods 
 
 
 
2.1. Cell cultures 
 
2.1.1. Mouse embryonic fibroblast cultures 
 
EB medium 
 Concentration Supplier 
FCS 10% Gibco, heat inactivated 30 
min at 55°C 
Non-Essential Amino Acids 1x Gibco # 11140-035 
Glutamine 100x (200 mM) 1x (2 mM) Gibco # 25030-024 
β-mercaptoethanol 0.001% Sigma # M7522 
DMEM To final volume Gibco # 21969-035 
 
 
ES medium 
 Concentration Supplier 
FCS 15% Gibco, heat inactivated 30 
min at 55°C 
LIF 103 unit/ml  
(approx. 10 ng/ml) 
Chemicon, # ESG1107, 107 
units/ml leukemia inhibitory 
factor  
Non-Essential Amino Acids 1x Gibco # 11140-035 
Glutamine 100x (200 mM) 1x (2 mM) Gibco # 25030-024 
β-mercaptoethanol 0.001% Sigma # M7522 
DMEM To final volume Gibco # 21969-035 
 
 16
Immortalized mouse embryonic feeders (MEFs) were grown in EB medium on 0.2% 
gelatin (Sigma # G-1890) coated tissue culture dishes (Nunc # 150288) for 2-4 days at 
37°C (7% CO2). As soon as they reached confluence, they were inactivated with 10 
μg/ml Mitomycin C (Sigma # M0503) for 2 hours at 37°C, washed with PBS (Gibco # 
14190) and let recover, for at least 2 hours, in ES medium until ES cells were plated on 
them. 
 
2.1.2. Mouse embryonic stem cells cultures 
 
N2 medium 
  Final concentration  Supplier 
Human Apo-Transferrin 50 µg/ml Sigma # T-1147 
Insulin 25 µg/ml Sigma # I-6634 
BSA 50 µg/ml Sigma # A-9418 
Progesterone 6 ng/ml Sigma # P-8783 
Putrescine 16 ng/ml Sigma # P-7505 
L-Glutamine 0.146 mg/ml Gibco # 25030-024 
Sodium Selenite 5.19 ng/ml Sigma # S-5261 
DMEM & F12 Mixed 1:1 to final 
volume of 250 ml 
Gibco # 21969-035 
Gibco # 21765-029 
 
 
Complete medium 
Aqueous solutions Stock sol. Final conc. Supplier 
L-Alanine 2 mg/ml 2 µg/ml Sigma # A-7627 
Biotine 0.1 mg/ml 0.1 µg/ml Sigma # B-4501 
L-Carnitine 2 mg/ml 2 µg/ml Sigma # C-0283 
Ethanolamine 1 mg/ml 1 µg/ml Sigma # E-9508 
D+ Galactose 15 mg/ml 15 µg/ml Sigma # G-0625 
L-Proline 7.76 mg/ml 7.76 µg/ml Sigma # P-0380 
Putrescine 16.1 mg/ml 16.1 µg/ml Sigma # P-7505 
Na-Selenite 0.016 mg/ml 0.016 µg/ml Sigma # S-1382 
Vit. B12 0.34 mg/ml 0.34 µg/ml Sigma # V-2876 
Zinc Sulfate 0.194 mg/ml 0.194 µg/ml Sigma # Z-4750 
Gluthation 1 mg/ml 1 µg/ml Sigma # G-6013 
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SOD 2.5 mg/ml 2.5 µg/ml Sigma # S-2515 
       
Ethanol solutions Stock solution. Final conc. Supplier 
Linoleic acid 100 mg/ml 1 µg/ml Sigma # L-1376 
Linolen acid 100 mg/ml 1 µg/ml Sigma # -2376 
Progesterone 0.63 mg/ml 6.3 ng/ml Sigma # P-8783 
all trans Retinol 10 mg/ml 100 ng/ml Sigma # R-7632 
Retinylacetat 10 mg/ml 100 ng/ml Sigma # R-7882 
Tocopherol 100 mg/ml 1 µg/ml Sigma # T-3251 
Tocopherolacetat 100 mg/ml 1 µg/ml Sigma # T-3001 
 
For 400 ml complete medium, 1 gr BSA (Sigma # A-9418), 2 mg transferrin (Sigma # T-
1147) and 1.6 mg Insulin (Sigma # I-6643) are dissolved in 30 ml DMEM and the 
remaining components are added. DMEM is added to final volume and medium is 
filtered and stored at 4°C for several weeks. Glutamine is added freshly before using the 
medium. 
 
The MECP2 mutant ES cell lines were a gift from Adrian Bird and Jacky Guy 
(Edinburgh, UK). ES cells were cultured and differentiated into neurons as described 
previously (Bibel et al., 2007, Bibel et al., 2004). Briefly, murine embryonic stem cells 
were grown on inactivated MEFs for 3-6 passages at 37°C (7% CO2) in the ES medium 
containing Leukemia Inhibitory Factor (Bilguvar et al.), at 103 unit/ml, to avoid the 
differentiation. Cells were splitted 1/10 every second day, the medium was changed every 
other day. ES cells were then passed on gelatin-coated dishes until no MEF were present. 
As soon as a homogeneous monolayer of ES cells was obtained, 4 million cells were 
plated on bacterial dishes (Greiner, Bio-one 94/16 with vents, # 633102) in EB medium 
where ES cells form cellular aggregates. Every second day the medium was changed, 
from day 4, after plating, retinoic acid (Sigma, # R-2625; final conc. 5 μM) was added to 
the medium. On day 8 the aggregates were dissociated with freshly prepared trypsin 
(Sigma, # T-8802; 0.05% trypsin in 0.04% EDTA/PBS) and the neuronal precursors 
plated on poly-D-ornitine (Sigma # P-8638) and laminin (Mencarelli et al., 
11234217001) coated 6-well plates (5 millions precursors in each well) in N2 medium. 
After 2 days the medium was replaced by complete medium. 
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2.1.3. Primary cortical neurons cultures 
 
Cerebral cortex of E16 mouse embryos were dissected in PBS containing glucose (0.2%) 
and BSA (0.1%), and treated with 0.5% trypsin for 10 min at 37°C flowed by mechanical 
dissociation. After centrifugation (5 min at 1’000 rpm), cells were plated in Neurobasal 
medium (Gibco # 21103), supplemented with B27 (Invitrogen # 080085-SA) 2%, 
glutamine 0.2 mM, and Pen/Strep (Invitrogen # 15140122) at a density of 125’000 
cell/cm2 in cell culture plates, with or without glass cover-slips, treated overnight with 
100 µg/ml poly-L-lysine (Sigma # 25988-63-0). 
 
2.1.4. Primary cortical glial cultures 
 
Cerebral cortex of P2 mice were dissected in PBS containing glucose (0.2%) and BSA 
(0.1%), and treated with 0.5% trypsin for 10 min at 37°C flowed by mechanical 
dissociation. After centrifugation (5 min at 1’000 rpm), cells from each brain were plated 
onto one 10-cm cell culture dish in the medium containing 20% FCS, 1% non-essential 
amino acids, 0.2 mM glutamine, DMEM and Pen/Strep. Lack of appropriate coating for 
neurons and usage of serum containing medium eliminate the chance of neuronal survival 
while it provides the condition for growth of glia. At the time of plating, the genotype of 
the pups was not known and tail samples were used for subsequent genotyping. 
 
2.1.5. HEK-293 cells cultures 
 
HEK-293 cells were cultured in EB medium containing 10% FCS, 1% non-essential 
amino acids, 0.2 mM glutamine, DMEM and Pen/Strep at 37°C (5% CO2). 
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2.2. Western blot  
 
Cells were collected ice cold PBS and lysed on ice for 30min using RIPA buffer (Tris-
HCl 25 mM pH 8.0, NaCl 150 mM, Triton X-100 1%, Sodium Deoxycholate 1%, SDS 
0.1%), containing protease inhibitors (Complete Protease Inhibitor Cocktail Tablets; 
Roche # 11697498001) and phosphatases inhibitors (Phosphatases inhibitors Cocktails 1 
and 2, Sigma # P2850 & P5726). Supernatants were collected after 30 min centrifugation 
at 12’000g and protein concentration was determined by BCA assay (BCA Protein Assay, 
Pierce # 23225). Equal amounts of total protein were loaded and separated by 
electrophoresis using NOVEX 4-12% gradient SDS-polyacrylamide gels (Invitrogen # 
EC60352BOX), and transferred to nitrocellulose membranes (GE Biosciences # 
RPN3032D). For quantitative Western blotting, equal numbers of nuclei were loaded in 
the gel instead of equal amount of proteins. Primary antibodies and concentrations used 
are as follows:  
 
Antibody Dilution Supplier 
rabbit polyclonal anti-MeCP2 1:1’000 Millipore # 07-013 
rabbit polyclonal anti-Histone H3 1:3’000 Abcam # ab7766 
rabbit polyclonal anti-phospho- CREB 1:1’000 Upstate # 06-519 
mouse monoclonal anti-phospho-ERK1/2 1:2’000 Cell Signal # 9102 
mouse monoclonal anti-Synaptophysin 1:1’000 Sigma # S5768 
mouse monoclonal anti-Actin 1:10’000 Sigma # A2228 
mouse monoclonal anti-β-III-Tubulin 1:10’000 Covance # MMS-435P 
 
Secondary antibodies coupled to horseradish peroxidase were used at a final 
concentration of 1:10’000. Membranes were developed using ECL (GE Biosciences # 
RPN2106), or ECL-Plus reagents (GE Biosciences # RPN2132). Densitometric 
quantification was performed with the free software ImageJ. 
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2.3. Quantitative real-time RT-PCR 
 
Total RNA (0.5 µg) was extracted using RNeasy Plus Mini Kit (QIAGEN # 74134), 
reverse-transcribed using SuperScript-III Reverse Transcriptase (Invitrogen # 11754-050) 
and random primers (Invitrogen # AM5722G) according to manufacturer’s instructions, 
and re-suspended in a final volume of 400 µl. qRT-PCR reactions were performed in a 
final volume of 25 µl containing TaqMan Universal Master Mix (Mencarelli et al., 
4304437), 5 µl cDNA, specific primer sets for the mouse BDNF gene (exon VIII) or 
mouse GAPDH gene at 0.9 µM, and specific TaqMan probes (5’ modification: FAM and 
3’ modification: TAMRA) for each gene at 0.25 µM. The PCR was performed using an 
ABI Prism 7’000 Sequence Detection System (Applied Biosystems) in 96-Multiwell 
plates. The TaqMan primer/probes sets used are as follows: 
 
 
Primer/Probe Sequence 
BDNF forward primer 5’-GGG AGC TGA GCG TGT GTG A-3’ 
BDNF reverse primer 5’-CGT CCC GCC AGA CAT GTC-3’ 
BDNF TaqMan Probe 5’-CGA GTG GGT CAC AGC GGC AGA-3’ 
GAPDH forward primer 5’- TGT GTC CGT CGT GGA TCT GA-3’ 
GAPDH reverse primer 5’-CCT GCT TCA CCA CCT TCT TGA-3’ 
GAPDH TaqMan Probe 5’- CCG CCT GGA GAA ACC TGC CAA GTA TG-3’ 
 
 
The specific levels of the BDNF transcript were normalized to the levels for GAPDH 
according to the Ct method, and statistical significance was determined by the Student’s t-
test method. 
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2.4. Cloning and lentivirus generation 
 
To express the genes of interest with high efficiency in neuronal cultures a lentiviral 
system was used (Gascon et al., 2008). For the biosafety reasons, the lentiviral system 
used is composed of 3 vectors. Two of these vectors (pMD2.G psPax2, kindly provided 
by Prof. Didier Trono, Ecole Polytechnique Fédérale de Lausanne, Switzerland) encode 
for the viral backbone and the third one, pLL-Syn-DsRed-Syn-EGFP (Figure 2-1), is the 
vector introducing the desired gene into the viral genome to be delivered and expressed in 
the neurons. The human synapsin promoter, a neuron specific promoter, was used to 
ensure the expression of the desired genes in neurons. The dual promoter nature of the 
virus makes it possible that at the same time the gene of interest i.e. MECP2 and a 
reporter gene EGFP would be expressed. This way, efficiency of infection is monitored 
by assessing number of the cells expressing the EGFP protein under the fluorescence 
microscope. 
pLL-Syn-dsRed-Syn-EGFP
8844 bp
dsRed
CMV Promoter
WPRE
WPRE
Amp
5'-LTR
3'-LTR
EGFP
hSyn Promoter
hSyn Promoter
BamHI (3097)EcoRI (5626)
NotI (3794)
 
Figure 2-1 Schematic representation of the pLL-Syn-DsRed-Syn-EGFP lentiviral vector 
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In order to introduce our genes of interests into viral vector, the pLL-Syn-DsRed-Syn-
EGFP was digested with BamHI & NotI which resulted in removal of DsRed. 
 
To generate the pLL-Syn-CRE-Syn-EGFP, the CRE was amplified from the pcDNA-
CRE. To make sure that the CRE enters into the nucleus of the neurons, Nuclear 
Localization Signal (NLS) of the SV40 T Antigen (PKKKRKV) was inserted into the N-
terminal of the CRE right after the start codon. CRE contains a BamHI restriction site 
which would cause problem during the cloning procedure as the pLL-Syn-DsRed-Syn-
EGFP was digested with the BamHI. Therefore, a BglII restriction site was inserted into 
the amplifying primer of the CRE, as BglII is compatible with BamHI. The CRE 
amplifying primers are as follows: 
 
 
Primer  Sequence Features 
CRE forward Primer  5’-CG AGA TCT ATG CCT AAG 
AAG AAG AGA AAG GTG TCC 
AAT TTA CTG ACC GTA CAC 
CAA-3’ 
Bold letters: BglII 
restriction site  
Italic letters encode for the 
SV40 Tag NLS 
CRE reverse primer  5’-AA GCG GCC GCC TAA TCG 
CCA TCT TCC AGC AG-3’ 
Bold letters: NotI 
restriction site 
 
 
After amplification with PCR, the PCR product was digested with BglII and NotI and 
ligated with the digested vector. 
 
To amplify the wild-type MECP2, the total RNA from the wild-type ES cell-derived 
neurons was extracted and reverse-transcribed into cDNA which was subsequently used 
in the PCR reaction as the template. To make the MeCP2 detection easier, both in the 
Western blot and in the immunostaining, I inserted a c-myc tag in the N terminal of the 
MeCP2. The following primer sets were used to amplify MECP2: 
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Primer  Sequence Features 
MeCP2 forward 
Primer  
5’-CG AGA TCT ATG GAA CAA AAA 
CTC ATC TCA GAA GAG GAT CTG 
GTA GCT GGG ATG TTA GGG CTC 
AGG -3’ 
Bold letters: BglII 
restriction site  
Italic letters encode for 
the c-myc 
MeCP2 reverse 
primer  
5’- AA GCG GCC GCT CAG CTA 
ACT CTC TCG GTC ACG GG -3’ 
Bold letters: NotI 
restriction site 
 
 
The MeCP2 S421A was generated using the site directed mutagenesis kit (Stratagene # 
200518) according to the manufacturer’s instructions. The primers used for mutagenesis 
are as follows:  
 
Primer Sequence 
MeCP2 S421A forward 5’-CCC CGA GGA GGC GCA CTG GAA AGC GAT GGC 
TG-3’ 
MeCP2 S421A reverse 5’-CAG CCA TCG CTT TCC AGT GCG CCT CCT CGG 
GG-3’ 
 
 
Similar to the CRE, the PCR product was digested with BglII & NotI and ligated into the 
digested pLL-Syn-Syn-EGFP vector. 
 
To produce the lentivirus, the 3 vectors were transfected in roughly 50% confluent HEK-
293 cells using Fugene-6 reagent (Mencarelli et al., 11814443001). Three days post 
transfection, lentiviruses were concentrated from the medium of HEK-293 cells using 
Lenti-X concentrator (Clontech # 631232), resuspended in the complete medium and kept 
at -80°C until used. 
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2.5. Assessment of the cell proliferation 
 
For the ES cells, progenitors and neurons, the cells were washed with warm PBS and 
trypsinized and counted using a cell counter (NucleoCounter, Chemometec). For ES cells 
that had formed aggregate, they were trypsinzied with freshly prepared trypsin (0.05% 
trypsin in 0.04% EDTA/PBS). EB medium was used to inactivate the trypsin and 
aggregates were further dissociated by pipetting up and down. The cells were then 
filtered using 40 µm Nylon cell strainer (BD Falcon # 352340) and counted using the cell 
counter.  
 
To assess the cell proliferation, 10 µM BrdU (Sigma # B5002) was added to the cultures 
of progenitors, on glass coverslips, for a period of 30 minutes after which cells were 
washed once with warm PBS and fixed with 4% Paraformaldehyde (PFA) for 15 minutes 
at 37°C. The staining was done with the BrdU Detection Kit II (Mencarelli et al., 
11299964001) according to the manufacturer’s instructions. The number of the cells with 
dark nuclei (stained for the BrdU incorporated in the nucleus) was divided to total 
numbers of the cells in each picture to calculate the percentage of the cells dividing 
within the BrdU pulse. Student t-test was used to perform the statistical analysis. 
 
 
 
2.6. Immunostaining and nuclear size measurement 
 
For immunocytochemistry (Ariani et al.), cells were grown on glass coverslips, washed 
twice with warm PBS, fixed for 15 minutes with 4% PFA at 37°C. Unspecific antibody 
binding was prevented with blocking solution (10% horse serum, 0.1% Tween 20 in PBS) 
for 1 hour at room temperature. The primary antibodies were added in the blocking 
solution and kept over night in the humid chambers at 4°C. Primary antibodies and 
dilutions used are as follows:  
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Antibody Dilution Supplier 
rabbit polyclonal anti-MeCP2 1:200 Millipore # 07-013 
mouse monoclonal anti-GFAP 1:500 Sigma # G3893 
rat monoclonal anti-CD11b 1:1’000 Abcam # ab6332 
mouse monoclonal anti-β-III-Tubulin 1:1’000 Covance # MMS-435P 
 
Secondary antibodies coupled to the fluorophore were all used at a final concentration of 
1:1’000. 
 
For immunohistochemitry, animals were heavily sedated by intraperitoneal injection of 
Ketalar (Parke Davies, 5 mg/kg) / Rompun (Bayer Health Care, 100 mg/kg) and perfused 
transcardially with 4% PFA in 1x PBS. The brains were removed and kept in fixative 
over night. Serial coronal 15-20 μm thick sections were obtained with a cryostat (Leica). 
The immunostaining of the brain sections has been performed similarly to that of cells in 
culture, starting with blocking. 
 
The free software ImageJ was used for nuclear size measurement. All the pictures were 
taken with 40X objective in our fluorescence microscope. In the software setting, 1 pixel 
was set equal to 0.115 µm. By putting a line around the hoechst nuclear staining the 
software calculates the surface of the nuclei automatically and student t-test was used for 
statistical analysis. 
 
 
2.7. Nuclei purification and in vitro transcription assay 
 
2.7.1. Nuclear purification from cultured cells 
 
Cell were washes twice with ice cold PBS and then collected with 1 ml of PBS 
containing the complete protease inhibitor (Mencarelli et al.) using a cell scraper. Cells 
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were transferred to an eppendorf tube and collected with centrifugation at 800 g for 5 
minutes. To lyse the cell membrane, the cellular pellets were resuspended in 10X volume 
of 250-STM, 0.1% NP40 (250 mM sucrose, 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2 and 
complete protease inhibitor) and kept on ice for 10 minutes then centrifuged at 800g for 
10 minutes. The pellet contains the nuclei and some cellular organelles. To get rid of 
these organelles and obtain highly pure nuclei, the nuclear pellets were resuspended in 1 
ml of 2M-STM (2 M sucrose, 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, and complete 
protease inhibitor) and centrifuged at 65’000g for 30 minutes. The pellet consists of 
highly purified nuclei. 
 
 
2.7.2. Nuclear purification from tissue 
 
Animals were scarified using CO2, the brain was taken out and the cerebral cortex 
isolated on ice cold metal block. The cerebral cortex then was sliced using a razor on the 
ice cold metal block until it lost its structure and became very soft and immediately 
transferred to a 2 ml glass douncer (Wheaton, USA) and homogenized in the presence of 
1 ml of 250-STM, 0.5% NP40 (250 mM sucrose, 50 mM Tris-HCl (pH 8.0), 5 mM 
MgCl2 and complete protease inhibitor) by 10 time up and down of the pistol. This 
mixed was transferred to an eppendorf tube and kept on ice for 10 minutes. After 10 
minutes of centrifugation at 800 g, the pellet was resuspended in 1 ml of 2 M-STM (2 M 
sucrose, 50 mM Tris-HCl (pH 8.0), 5 mM MgCl2, and complete protease inhibitor) and 
centrifuged at 65’000 g for 30 minutes. The pellet consists of highly purified nuclei 
(Figure 2.2). 
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Figure 2-2 Purified nuclei from cerebral cortex. Cerebral cortical nuclei were purified as described 
above and nuclei purity was assessed. (A) Phase contrast image of the purified nuclei (B) Hoechst staining 
of the nuclei (C) The Hoechst staining overlaps with the phase contrast boundaries of nuclei proving 
absence of cellular debris and high purity of the nuclei preparation 
 
 
 
2.7.3. In vitro transcription 
 
The nuclear pellets were resuspended in 600 µL 2X elongation buffer (100 mM Tris-HCl 
(pH 8.0), 5 mM MgCl2, 5 mM MnCl2, β-mercaptoethanol 10 mM and complete protease 
inhibitor). A dilution series of the nuclei was made for counting from 100 µL of the 
purified nuclei. The nuclei were counted using the cell counter (NucleoCounter, 
Chemometec). The number of the nuclei was adjusted, with 2X elongation buffer, to have 
desired numbers in 100 µL e.g. 250’000 nuclei in 100 µL. The in vitro transcription 
started by addition of 100 µL of the nuclei to 100 µL of the reaction mixture (ATP, CTP 
and GTP ribonucleotides each at a final concentration of 0.6 mM, 1 µCi of [32P]-UTP, 40 
units of RNase Inhibitor (Roche) in water). The reaction was performed at 37°C for 0, 30 
or 45 minutes. The reaction was stopped by addition of 800 µL of TRIzol (Invitrogen) to 
each tube. The RNA purification was performed according to the manufacturer’s 
instructions (TRIzol, Invitrogen). The radioactivity incorporated into total RNA was 
measured using tri-carb liquid scintillation counter (Packard) and student t-test used for 
the statistical analysis. 
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2.8. Animal work 
 
2.8.1. MECP2 mutant mice 
 
I used the MECP2 mutant mice generated by Adrian Bird (Guy et al., 2001). The mice 
were obtained from the Jackson Laboratory (stock number 003890; B6.129P2(C)-
Mecp2tm1.1Bird/J) and registered in the Biozentrum central animal facility as the code 
20250. As the male hemizygote mutants (MECP2 -/y) are sterile, the mating scheme is to 
breed wild-type B6 males with heterozygote (MECP2 +/-) females. As the MECP2 gene 
is located on the X chromosome in mice, like in humans, the off springs have one of the 
following genotypes: ♂ MECP2 +/y, ♂ MECP2 -/y, ♀ MECP2 +/+ or ♀ MECP2 +/-. 
The male knock-outs were used for the experimental purposes and their wild-type 
littermates as control. The heterozygote females were used for mating. The genotyping 
was done according to the protocol provided by the Jackson Laboratory for this line. All 
the experiment involving usage of wild-type and mutant mice were done under the 
official permission from the Basel Cantonal Veterinary (the code of approved permission: 
2299).  
 
2.8.2. BDNF ELISA measurements 
 
After sacrifice (see above), brains were removed and dissected to various parts on an ice 
cold metal block. Various parts were immediately shock frozen in the liquid nitrogen and 
stored at -80°C until used.  
 
The ELISA assays were performed using an optimized version of the protocol established 
in our laboratory (Kolbeck et al., 1999).  
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2.8.3. Running wheel assay 
 
To assess the locomotor performance of the mice, we used the running wheel assay. In 
this assay, mice are kept in the cages that contain a running wheel. This wheel is 
connected to a computer recording the distance ran by the mice. 3 days prior to start of 
experiment mice were moved to these cages to learn how to use the wheel and also get 
used to the environment of the new cage. Data on the running distances were 
automatically calculated and saved by the computer and student t-test used for the 
statistical analysis. 
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3. Results 
 
 
 
3.1. Neuronal differentiation of MECP2 mutant ES cell 
lines 
 
All MECP2 mutant ES cell lines were kindly provided by the group of Dr. Adrian Bird, 
University of Edinburgh, UK (Guy et al., 2007, Guy et al., 2001). All the mutations were 
generated in male (XY) E14 ES cells background used as wild-type control in all the 
experiments.  
 
3.1.1. MECP2 mutant ES cell lines 
 
The MECP2 gene contains 4 exons. Exon 1 codes for 24 amino acids, exon 2 encodes for 
9 amino acids, exon 3 encodes for 117 amino acids and the exon 4 encodes for the rest of 
the 357 amino acids as well as for the 3’UTR (Figure 3.1). 
 
Figure 3-1 MECP2 gene structure. Part of methyl-binding domain (MBD) is coded by the exon 3 and the 
rest by the exon 4. The transcriptional repressor domain (TRD) is entirely coded by the exon 4 as well as 
both of the nuclear localization signals (NLS) 
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Part of the methyl-binding domain (MBD) (Nan et al., 1997, Nan et al., 1993) is coded 
by exon 3 and the rest by exon 4. The transcriptional repressor domain (TRD) (Nan et al., 
1997) is entirely coded by the exon 4. In addition, both of the known nuclear localization 
signals of MeCP2 are encoded by exon 4. Considering the very small size of the first two 
exons of MECP2 and the fact that most of the protein, as well as all the well known 
functional domains are located in the exons 3 & 4, Guy and colleagues decided to flank 
the exon 3 and the entire protein coding part of the exon 4 by 2 loxP sites (Guy et al., 
2001). This led to the generation of a floxed allele of the MECP2 (MECP2 loxP/y). Upon 
Cre treatment of the loxP allele, a null allele of MECP2 was generated (MECP2 -/y) 
(Figure 3.2). 
 
Figure 3-2 Targeting strategy of the MECP2 gene to generate the flox and the null alleles (Adapted 
from Guy et al., 2001) 
 
For the reversal experiment (see introduction), Guy and colleagues inserted a stop 
cassette (both transcriptional and translational) flanked by 2 loxP sites between exon 2 
and 3 (Guy et al., 2007). This led to generation of MECP2 Stop/y allele in which the stop 
cassette prevents the expression/translation of the MeCP2 transcript. Upon Cre treatment 
of the MECP2 Stop/y allele, the stop cassette is removed leading to a re-expression from 
the endogenous promoter (Figure 3.3). 
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Figure 3-3 Targeting strategy of the MECP2 gene to generate the lox-Stop allele (Adapted from Guy et 
al., 2007) 
 
 
3.1.2. Neuronal differentiation of various MECP2 mutant ES cells 
 
The four ES cell lines (wild-type, MECP2 loxP/y, MECP2 -/y and MECP2 Stop/y) were 
differentiated into neurons according to the protocol of Bibel et al., 2004 and Bibel et al., 
2007. 
 
Regardless of the type of mutation, differentiation of all the four ES cell lines resulted in 
highly pure neuronal cultures which could be maintained easily for as longs as one month 
without any obvious degeneration. The levels of synaptophysin, a synaptic vesicular 
protein widely used as a marker of synapse formation and neuronal maturation (Calhoun 
et al., 1996), were assessed in the neuronal cultures obtained from MECP2 loxP/y and 
MECP2 -/y ES cells. Western blots were performed with cells lysed at day 4, 7, 14 and 
21 after dissociation of the cellular aggregates, by loading equal quantities of protein 
lysates from each sample. In both cultures, regardless of presence or absence of MeCP2, 
there is significant increase in the expression of synaptophysin between the first and the 
second week, indicating both wild-type and mutant neurons mature following a similar 
time course (Figure 3.4). 
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Figure 3-4 Both MECP2 loxP/y and MECP2 -/y neurons mature similarly in culture. Equal amounts of 
protein lysates from MECP2 loxP/y and MECP2 -/y ES cell-derived neurons at different ages (4, 7, 14 and 
21 DIV) were loaded in the SDS-gel and the expression of MeCP2 and Synaptophysin were assessed by 
immunoblotting. Tubulin β-III (Tuj-1) is used as the loading control 
 
To assess the expression levels of MeCP2 in neurons generated from various ES cell lines, 
Western blot analysis were performed with equal amounts of protein lysates obtained 
from the 2-weeks-old neuronal cultures (Figure 3.5). 
 
Figure 3-5 Expression of MeCP2 at protein levels in neurons generated from 4 ES cell lines with 
various mutations in the MECP2 gene. Equal amounts of protein lysates from wild type (MECP2 +/y), 
MECP2 -/y, MECP2 loxP/y and MECP2 Stop/y ES cell-derived neurons were loaded in the Western blot 
gel and the levels of MeCP2 were assessed by immunoblotting. Tubulin β-III (Tuj-1) is used as the loading 
control 
 
 
 
As expected, the wild-type (MECP2 +/y) ES cell-derived neurons have the highest 
expression of the MeCP2 while the MECP2 -/y neurons do not express any detectable 
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MeCP2. The MECP2 Stop/y neurons express very little, if any, MeCP2 which shows that 
the floxed-stop cassette inserted into the gene functions efficiently in preventing the 
expression of MeCP2. Interestingly, the MECP2 loxP/y neurons express MeCP2 at lower 
levels compared with wild-type neurons. This could be explained by the fact that to 
generate the floxed allele of MECP2, a neomycin selection cassette (Figure 3.2) was 
inserted into the 3’UTR of the gene in the exon 4 which led to the disruption of the 
3’UTR (Guy et al., 2001). This in turn could affect the translation efficiency/stability of 
the MeCP2 mRNA. In line with this, mice harboring this allele display abnormalities 
such as learning and motor deficits, decreased anxiety, altered social behavior and 
disrupted breathing patterns (Samaco et al., 2008).  
 
 
 
3.2. Progenitors lacking MeCP2 produce fewer neurons 
 
Despite the normal appearance of neuronal cultures generated from the MECP2 mutant 
ES cells, the MECP2 -/y neuronal cultures always ended up at a lower density than wild-
type cultures, in spite of identical plating densities. As it has been reported that MECP2 
mutant lymphocytes obtained from the human RTT patients proliferate slower than wild-
type lymphocytes (Balmer et al., 2002), I checked the effect of the lack of MeCP2 on cell 
proliferation.  
 
3.2.1. Loss of MECP2 does not affect the growth of ES cells  
 
Two wild-type ES cell lines (R1 and E14) and 2 different clones of MECP2 -/y ES cells 
were used to make sure that the data obtained on proliferation are solely due to presence 
or absence of MeCP2 rather than any line or ES cell clone-specific behavior. Proliferation 
of ES cells were measured at two stages of differentiation: ES cells in monolayer and the 
cellular aggregate stage (Bibel et al., 2007, Bibel et al., 2004) 
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After the third passage on gelatin coated plates (see materials and methods), equal 
numbers of ES cell (7.5 millions), from each genotype (wild-type and MECP2 -/y) were 
plated in 10-cm dishes in quadruplicate. Forty eighth ours later, the numbers of ES cells 
produced were counted using a cell counter. Interestingly, proliferation of ES cells 
lacking MeCP2 was not significantly different from the wild-type ES cells (wild-type: 
62.44 million ± 2.871 millions, N = 8, MECP2 -/y: 66.81 millions ± 1.562 millions, N = 
8, P = 0.0654, Student t-test). 
 
Similarly, cellular aggregates were generated from equal numbers of both wild-type and 
MECP2 -/y ES cells and the number of the cells counted after 2, 4 and 8 days (Table 3.1). 
 
 
Table 3-1 Proliferation of wild-type and MECP2 -/y mutant ES cells assessed at aggregate stage. 
Number of the cells (shown in millions) generated from 4 millions ES cells after 2, 4 and 8 days were 
counted and the data shown as mean ± S.E.M 
 
 Day 2 (N=3) Day 4 (N=3) Day 8 (N=4) 
Wild-type 29.27 ± 1.67  23.00 ± 0.577  24.13 ± 1.375  
MECP2 -/y 29.00 ± 0.577  24.33 ± 1.856  20.10 ± 2.050  
 
These experiments revealed that the lack of MeCP2 does not affect the proliferation of 
ES cells at the stage of cellular aggregates (Figure 3.6). However, the number of cells 
obtained from the MECP2 -/y ES cells at 8 days i.e. 4 days post-treatment with retinoic 
acid, was slightly less than number of cells generated from wild-type ES cells, although 
the differences do not reach statistical significance (Figure 3.6). 
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Figure 3-6 Proliferation of ES cells, both in monolayer and in cellular aggregate stage, is not affected 
by presence or lack of MeCP2. Cell numbers at each stage were normalized to the values obtained from 
wild-type ES cells and shown as mean ± S.E.M 
 
ES cells were found to express very low levels of MeCP2 compared to neurons (Figure 
3.7.A) and retinoic acid treatment to significantly induce the expression of MeCP2 
(Figure 3.7.B).  
 
 
Figure 3-7 MeCP2 expression in ES cells in monolayer and cellular aggregate stages and in ES cell-
derived neurons (A) Western blot analysis with one million purified nuclei from 10 DIV ES cell-derived 
 37
neurons and ES cells in monolayer (before aggregation) show significantly lower levels of MeCP2 
expression in ES cells compared to the neurons. The arrow head points to the band corresponding to the 
MeCP2 protein (B) MeCP2 mRNA levels measured by quantitative real-time RT-PCR in cellular 
aggregates before and 4 days after treatment with retinoic acid shows a significant induction of MeCP2 
expression by retinoic acid treatment (values shown as mean ± S.E.M, N=3) 
 
 
 
3.2.2. Progenitors lacking MeCP2 generate fewer neurons compared with 
wild-type cells 
 
 
As the absence of MeCP2 had no effect on proliferation of ES cells, the question arose if 
the proliferation of neuronal progenitors would be affected compared with wild-type cells. 
Indeed, before neuronal differentiation, the ES cell-derived progenitors go through one or 
even 2 rounds of cell division. Wild-type and MECP2 -/y aggregates were dissociated at 
day 8 and 5 millions progenitors were plated onto poly-ornitin/laminin coated plates. 
Subsequently, the cultures were trypsinsed at different time points and the number of 
cells was counted using a cell counter. While after 6 days the number of neurons 
generated from wild-type ES progenitors was significantly higher than the staring cell 
number plated (Table 3.2), the number of neurons generated from MECP2 -/y progenitors 
was not. 
 
 
Table 3-2 Effect of lack of MeCP2 on proliferation of the neuronal progenitors. Number of cells 
(millions) generated from the initial 5 millions of progenitors plated at DIV 0 from both genotypes; wild-
type and MECP2 -/y. In all case the values are shown as mean ± S.E.M, N= 6 
 
 Day 0 Day 1 Day 2 Day 3 Day 6 
Wild-type 5 4.70 ± 0.11 6.63 ± 0.41 8.52 ± 0.22 8.80 ± 0.39 
MECP2 -/y 5 3.31 ± 0.37 4.00 ± 0.64 4.62 ± 0.79 4.44 ± 0.72 
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Figure 3-8 MeCP2-deficient neuronal progenitors produce fewer neurons than wild-type progenitors. 
(A) The number of cells almost double after plating wild-type progenitors while this increase is absent in 
cells lacking MeCP2 (mean ± S.E.M, **P<0.01, Student t-test) (B) Phase contrast picture of wild-type and 
MeCP2-deficient progenitors at DIV 1 
 
The increase in the cell number of the wild-type progenitors coincides with a marked 
increase in the expression of MeCP2 at the protein levels (Figure 3.9). 
 
Figure 3-9 MeCP2 expression increases 
with neuronal maturation. Equal 
amounts of wild-type ES cell-derived 
neuron lysates (1, 3 and 8 DIV) were 
loaded on SDS-gel and MeCP2 expression 
was assessed by immunoblotting. A 
significant increase in the expression of 
MeCP2 during the first week post-
dissociation of aggregates is evident. The 
Actin and Tuj-1 were used as loading 
controls 
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3.2.3. Neuronal progenitors lacking MeCP2 proliferate less than wild-type 
progenitors 
 
In addition to reduced proliferation of progenitors, the smaller number of neurons 
generated from the MECP2 -/y ES cells could also be explained by increased cell death. 
However, as RTT brains show no obvious degeneration or atrophy (Chahrour and Zoghbi, 
2007), I then decided to assess the effect of lack of MeCP2 on proliferation. Two hours 
after dissociation, cultures of wild-type and MECP2 -/y progenitors were exposed to 30 
minutes of BrdU pulse, a modified analogue of cytosine that is only incorporated in the 
nuclei of dividing cells. Cells were then fixed and stained with an antibody against BrdU. 
Quantification of the BrdU labeling shows that while more than half of the cells in wild-
type cultures incorporate BrdU within 30 minutes pulse, much fewer (almost 27%) of the 
MECP2 -/y progenitors incorporate the BrdU (Figure 3.10). 
 
Figure 3-10 Proliferation defect of the MeCP2-deficient neuronal progenitors. (A) Phase contrast 
image of wild-type (MECP2 +/y) and MECP2 -/y progenitors pulsed with BrdU for 30 minutes, 2 hours 
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post-dissociation. The dark labelled nuclei are those that have incorporated BrdU (B) To quantify the 
percentage of the cells incorporating BrdU, the number of cells with dark nuclei was divided by the total 
number of cells (mean ± S.E.M, *** P<0.0001, Student t-test) 
 
 
 
3.3. MeCP2 regulates the size of neuronal nuclei 
 
Beside their lower density, the neurons obtained from the MECP2 -/y ES cells looked 
very similar to wild-type neurons. However, closer examination revealed that they have 
smaller nuclei compared with the wild-type neurons. As MeCP2 is a nuclear protein and 
the size and shape of nuclei is thought to have a direct correlation with chromosome 
localization and gene expression (Trinkle-Mulcahy and Lamond, 2008), I decided to 
assess the regulation of neuronal nuclear size by MeCP2 in more detail. While, this 
phenotype has already been reported in some brain areas of mice lacking MeCP2 (Chen 
et al., 2001), this aspect of MeCP2 research has not been followed up. In particular, it is 
unknown if it affects only neurons or other cell types, if it is cell autonomous or not, or 
even if it appears during development or it is part of a regressive event occurring only 
after the disease begins to be established.  
 
3.3.1. Nuclei lacking MeCP2 fail to grow during neuronal maturation 
 
The size of nuclei was determined at day 3, as by this time most progenitors have already 
dropped out of the cell cycle so I would avoid any variation in the nuclear size as a result 
of the mitosis. 8 days was chosen as the time point representing young neurons (Figure 
3.4) and 26 days mature neurons. During the transition from progenitors to young 
neurons a significant increase in the size of neuronal nuclei was found in wild-type 
neurons (Table 3.3). The nuclei of the wild-type neurons continue growing with 
maturation as the nuclei of the 26 days in vitro (DIV) old wild-type neurons were again 
significantly bigger than the nuclei of the 8 DIV neurons. 
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When measured at 3 days in vitro culture, the nuclei of the MECP2 -/y neurons were of 
the same size of aged matched wild-types but at 8 days in vitro culture while the nuclei of 
the wild-types had enlarged significantly, the nuclei of the MECP2 -/y neurons failed to 
grow (Figure 3.11) and remained at the same size as the nuclei of the 3 days in vitro 
neurons.  
 
Table 3-3 Quantification of nuclear size of wild-type and MECP2 -/y neurons (mean ± S.E.M) 
 
 DIV 3 DIV 8 DIV 26 
MECP2 +/y 19.67 µm2 ± 0.4072 µm2 27.78 µm2 ± 0.3033 µm2 31.68 µm2 ± 1.186 µm2 
MECP2 -/y 19.97 µm2 ± 0.3869 µm2 19.32 µm2 ± 0.1902 µm2 23.40 µm2 ± 0.677 µm2 
 
 
 
Figure 3-11 Nuclei of the MECP2 -/y neurons fail to grow. (A) ES cell-derived neurons were stained at 
DIV 8 with antibodies against the neuron specific marker Tuj-1 and the 4',6-diamidino-2-phenylindole 
(DAPI), a fluorescent dye that binds to DNA. DAPI staining shows that the nuclei of the MECP2 -/y 
neurons are smaller than wild-types (B) Quantification of nuclear surface of neurons during the course of 
neuronal maturation (mean ± S.E.M, *** P<0.0001, Student t-test) 
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The increase in the nuclear size of wild-type neurons from day 3 to 8 is accompanied 
with a significant increase in the expression of MeCP2 (Figure 3.9). During this time 
period, the size of mutant nuclei remains constant. 
 
 
3.3.2. Nuclear size of ES cell-derived neurons correlates with their levels of 
MeCP2 
 
At 3 days in vitro, the nuclei of neurons generated from either wild-type or the 3 mutant 
ES lines were essentially of the same size (Table 3.4). But, at 8 days in vitro, the MECP2 
-/y and MECP2 Stop/y both had smaller nuclei compared to the wild-type neurons. The 
size of the nuclei of MECP2 loxP/y neurons was between that of wild-type and MECP2 -
/y (Figure 3.12). 
 
 
Table 3-4 Quantification of nuclear sizes of ES cell-derived neurons with various mutations in 
MECP2 at DIV 3 and 8 (mean ± S.E.M) 
 
 DIV 3 DIV 8 
MECP2 +/y 19.50 µm2 ± 0.3326 µm2 27.64 µm2 ± 0.2648 µm2 
MECP2 -/y 19.96 µm2 ± 0.4292 µm2 19.18 µm2 ± 0.159 µm2 
MECP2 loxP/y 20.46 µm2 ± 0.373 µm2 24.51 µm2 ± 0.4331 µm2 
MECP2 Stop/y 20.56 µm2 ± 0.3829 µm2 20.15 µm2 ± 0.3970 µm2 
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Figure 3-12 The size of nuclei in ES cell-derived neurons correlates with their levels of MeCP2. 
Quantification of nuclear size of wild-type and MECP2 mutant neurons during the course of neuronal 
maturation (mean ± S.E.M, *** P<0.0001, Student t-test) 
 
 
 
3.3.3. Primary neurons of MECP2-deficient mice have smaller nuclei 
 
To check whether the small nuclei phenotype related to the absence of MeCP2 can also 
be observed in primary cultures, neurons were dissociated from the cerebral cortex of 
wild-type and MECP2 -/y embryos (see Materials and Methods) and nuclear size 
determined.  
 
Cortex of E16 embryos were dissected one by one and genotyping performed on tails of 
embryos after plating. After 16 days in vitro, the nuclei of MECP2 -/y cortical neurons 
(30.19 µm2 ± 0.7291 µm2; N = 49) were significantly smaller than that of wild-type 
(38.61 µm2 ± 1.159 µm2; N = 26) cortical neurons (Figure 3.13). 
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Figure 3-13 MeCP2-deficient cortical neurons have small nuclei. (A) Cortical neurons dissociated from 
brains of wild-type and MECP2 -/y embryos were stained with antibodies against the neuron specific 
marker Tuj-1. The nuclei were stained with DAPI. Smaller nuclei of the MECP2 -/y cortical neurons in 16 
DIV cultures is evident compared to the wild-types (B) Quantification of nuclear size of wild-type and 
MECP2 -/y neurons at 16 DIV (mean ± S.E.M, *** P<0.0001, Student t-test) 
 
 
 
MeCP2 levels were also assessed by Western blot analysis in 8 DIV wild-type ES cell-
derived neurons compared with 16 DIV cortical neurons (Figure 3.14). They were found 
to be comparable. 
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Figure 3-14 Similar levels of MeCP2 in wild-type cortical and ES cell-derived neurons. Western blot 
analysis on 0.1, 0.2 and 0.4 million purified nuclei comparing the levels of MeCP2 amongst wild-type ES 
cell-derived neurons at 8 DIV and cortical neurons at 16 DIV. MECP2 -/y neuronal lysates were used as 
negative control for MeCP2 detection. The histone H3 was used as a loading control. 
 
 
 
3.3.4. Re-expression of MeCP2 rescues the small nuclei phenotype 
 
As the lack of MeCP2 both in ES cell-derived neurons and cortical neurons was found to 
be associated with small nuclei phenotype, re-expression of MeCP2 was then attempted. 
Infection of MECP2 Stop/y neurons by Cre-encoding lentiviruses was used for this 
purpose. MeCP2 re-expression was then assessed by Western blot analysis (Figure 3.15). 
MECP2 Stop/y neurons that were infected with the Cre lentivirus at DIV 2 had 
significantly bigger nuclei than the neurons that were infected with GFP-encoding 
lentivirus at DIV 8 (GFP virus infected: 22.01 µm2 ± 0.4949 µm2; N = 49, Cre virus 
infected: 31.87 µm2 ± 0.8158 µm2; N = 51). 
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Figure 3-15 Re-expression of MeCP2 rescues the small nuclei phenotype. (A) Infection of MECP2 
Stop/y neuronal culture at DIV 2 with Cre-encoding lentivirused led to a re-expression of MeCP2 from the 
endogenous promoter, as assessed by Western blot at DIV 8, while control (GFP) virus did not affect the 
MeCP2 expression (B) Quantification of nuclear surface at DIV 8 in MECP2 Stop/y neurons infected with 
either GFP or Cre encoding lentiviruses (mean ± S.E.M, *** P<0.0001, Student t-test) 
 
In a complementary approach, MeCP2 was expressed in MECP2 -/y ES cell-derived 
neurons using the same viral delivery system. Knock-out neurons were infected with 
either a control virus (GFP) or a virus coding for MeCP2 at 2 days in vitro and nuclear 
size was measured 6 days later at 8 DIV. Over-expression of MeCP2 in the knock-out 
neurons led to a significant enlargement of the nuclei and rescued the small nuclei 
phenotype (control infected nuclei: 20.95 µm2 ± 0.4362 µm2; N = 51, MeCP2 infected 
nuclei: 30.01 µm2 ± 0.8065 µm2; N = 53).  
 
To test the possibility that phosphorylation of serine 421 is critical (see Zhou et al., 2006), 
the MECP2 -/y neurons were also infected at 2 DIV with either control (GFP) virus or a 
virus coding for MeCP2 mutant with a substitution of serine 421 for alanine (S421A) and 
the nuclear size was measured at 8 DIV. MeCP2 S421A could also rescue the small 
nuclei phenotype, to the same extend, as the wild type MeCP2 (MeCP2 S421A infected 
nuclei: 28.85 µm2 ± 0.8017 µm2; N = 42). The size of the nuclei of the neurons over-
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expressing either wild-type MeCP2 or MeCP2 S421A was indistinguishable (Figure 
3.16).  
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Figure 3-16 Over-expression of both wild-type and non-phosphorylateable forms of MeCP2 (S421A) 
rescue the small nuclei phenotype in the MECP2 -/y neurons. MECP2 -/y neurons were infected at DIV 
2 with control (GFP), wild-type MeCP2 or MeCP2 S421A encoding lentiviruses. The nuclear sizes of the 
infected neurons were measured at DIV 8 and shown in this plot (mean ± S.E.M, *** P<0.0001, Student t-
test) 
 
3.3.5. Regulation of nuclear size by MeCP2 is cell autonomous 
 
Recently, a role for MeCP2 in non-neuronal cells has bee proposed (see Discussion) 
raising the possibility that the lack of MeCP2 may affect neuronal function indirectly. To 
test whether or not the small nucleus phenotype observed in the absence of MeCP2 is cell 
autonomous or not, MECP2 -/y neurons were infected with the viruses coding for MeCP2 
at 2 DIV. 18 days later, the nuclear size of the MeCP2 over-expressing and the non-
infected neurons in this culture were compared to that of neurons of non-infected sister 
cultures. While the nuclear size of the MECP2 -/y neurons over-expressing MeCP2 had 
enlarged (31.16 µm2 ± 0.6361 µm2; N = 132) and the small nuclei phenotype was rescued, 
the nuclei of the neighboring non-infected neurons (22.02 µm2 ± 0.4081 µm2; N = 89) 
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remained as small as nuclei of the control neurons from the non-infected sister cultures 
(22.67 µm2 ± 0.4320 µm2; N = 108) (Figure 3.17). 
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Figure 3-17 Regulation of the neuronal nuclei size by MeCP2 is cell autonomous. The nuclear size of 
MECP2 -/y neurons at DIV 20 in non-infected culture was compared to that of the MECP2 -/y neurons 
infected with MeCP2 encoding lentiviruses at DIV 2 and the nuclear size of non-infected MECP2 -/y 
neurons in the culture where the MeCP2 encoding was added. While over-expression of the MeCP2 in 
MECP2 -/y neurons (rate of infection > 50%) rescues the small nuclei phenotype, the non-infected 
neighbouring neurons remain as small as knock-out neurons in non-infected sister culture (mean ± S.E.M, 
*** P<0.0001, Student t-test) 
 
3.3.6. MeCP2-deficient glia do not have small nuclei 
 
Given a possible role of MeCP2 in astrocytes (see Discussion), the nuclear size of non-
neuronal cells was also assessed with a focus on primary astrocytes and microglia from 
the brains of wild-type and MECP2 -/y young mice. Glial cultures were prepared from 
the brain of P2 pups (see Materials and Methods) and nuclear size was measured 2 weeks 
later. 
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The expression of MeCP2 was also assessed in astrocytes and microglial cells. 
Antibodies against GFAP (Glial fibrillary acidic protein) were used to detect the 
astrocytes and microglia were detected using antibodies against CD11b (cluster of 
differentiation molecule 11b or Integrin alpha M). 
 
Immunostaining using antibodies against MeCP2 revealed a clear staining of MeCP2 in 
the nuclei of astrocytes, but not above the background in the wild-type microglia using 
MECP2 -/y glial cultures as antibody specificity control. 
 
 
 
 
Figure 3-18 Astrocytes, but not microglial cells, express detectable levels of MeCP2. Immunostaining 
of glial culture obtained from brain of wild-type mice shows a clear staining of MeCP2 in the nuclei of 
astrocytes (GFAP stained) but not in the nuclei of microglia (CD11b stained). MECP2 -/y glia were used to 
verify the MeCP2 staining 
 
 
To compare the levels of MeCP2 in astrocytes with neuron, I performed semi-
quantitative Western blot analysis. A dilution series of pure nuclei of astrocytes, DIV 3 
and 8 wild-type ES cell-derived neurons and nuclei of MECP2 -/y neurons as negative 
control were loaded in the SDS-gel for immunoblotting against MeCP2 (Figure 3.19). 
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Figure 3-19 Astrocytes express similar levels of MeCP2 compared to the 8 DIV ES cell-derived 
neurons. Semi-quantitative Western blot on 0.1, 0.2 and 0.4 millions of nuclei of astrocytes, DIV 3 & DIV 
8 ES cell-derived neurons. Nuclei of MECP2 -/y neurons were used as the negative control for the MeCP2 
detection. Histone H3 was used a the loading control 
 
 
 
These results indicate that the levels of MeCP2 in primary astrocytes are comparable to 
those found in 8 days old ES cell-derived neurons. As I have shown that 8 DIV ES cell-
derived neurons have similar levels of MeCP2 compared to the 16 DIV primary cortical 
neurons (Figure 3.14), it seems then that astrocytes, at least in vitro, express levels of 
MeCP2 similar to those found in mature neurons. However, the size of the nuclei of wild-
type astrocytes was found not to differe from nuclei of MECP2 -/y astrocytes (wild-type: 
79.50 µm2 ± 1.126 µm2; N = 85, MECP2 -/y: 77.32 µm2 ± 1.140 µm2; N = 82) 
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Figure 3-20 MeCP2 does not regulate the nuclear size of astrocytes. (A) Immunostaining of primary 
astrocytes (GFAP stained) obtained from brain of wild-type and MECP2 -/y mice. A clear staining of 
MeCP2 in wild-type astrocytes, which is absent in nuclei of MECP2 -/y astrocytes, colocalizes with the 
hoechst staining of the nuclei (B) Quantification of the nuclear size reveals no difference between wild-type 
and MECP2 -/y astrocytes (mean ± S.E.M) 
 
Although MeCP2 is not detectable in microglial cells, nuclear size was also compared 
between wild-types and MECP2 -/y microglia. Nuclear size measurement revealed that, 
much like in case of astrocytes, the wild-type (29.76 µm2 ± 0.518 µm2; N = 62) and 
MECP2 -/y (29.81 µm2 ± 0.614 µm2; N = 69) microglia also have similar sizes of nuclei 
(Figure 3.21) which shows the nuclear size of these 2 types of glial cells is not regulated 
by MeCP2. 
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Figure 3-21 Wild-type and MECP2 -/y microglia have similar nuclear sizes. (A) Immunostaining of 
primary microglia (CD11b stained) obtained from brain of wild-type and MECP2 -/y mice. No staining of 
MeCP2, above background, is detected in the wild-type microglia (B) Quantification of the nuclear size 
(mean ± S.E.M) reveals no significant difference in the nuclear size between the wild-type and MECP2 -/y 
microglia 
 
 
3.3.7. In vivo measurements of neuronal nuclei size 
 
The size of neuronal nuclei was then measured in the CA3 area of the hippocampus in 1-
week and of 7 months-old mice (Figure 3.22). Much like the in vitro situation, there is a 
significant increase in neuronal nuclear size during the development between 1 week 
after birth (46.88 µm2 ± 0.5229 µm2; N = 304) and 7 months (82.76 µm2 ± 1.388 µm2; N 
= 258). 
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Figure 3-22 Enlargement of the neuronal nuclei in the CA3 are of the hippocampus. (A) DAPI 
staining of the nuclei in CA3 area of the hippocampus in 1 week and 7 months old wild type mice (B) 
Quantification of nuclear size in CA3 area shows a significant increase (mean ± S.E.M, *** P<0.0001, 
Student t-test) in the nuclear size with age 
 
 
 
In the CA3 area of hippocampus of 2 months old mice lacking MeCP2, the neuronal 
nuclei were significantly smaller (Figure 3.23) than wild-type nuclei (wild-type: 50.52 
µm2 ± 0.609 µm2; N = 185, MECP2 –/y: 38.35 µm2 ± 0.270 µm2; N = 322) 
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Figure 3-23 Neurons in CA3 area of hippocampus of MECP2 -/y mice have small nuclei. 
Quantification of neuronal nuclear size in CA3 area (mean ± S.E.M, *** P<0.0001, Student t-test) 
 
 
 
3.3.8. Reduced rate of global transcription in MeCP2-deficient neurons 
 
 
To begin to test for possible functional impact correlating with the small nuclei 
phenotype, I then measured the global rates of transcription using a modified form of 
nuclear run-on assay. After incubation of purified nuclei with unlabeled ATP, CTP, GTP 
and radio-labelled [32P]-UTP, total RNA was extracted and then amount of radioactivity 
incorporated in the total RNA was measured (Thompson, 1973) in the nuclei of wild-type 
and MECP2 -/y neurons at 3, 8 and 13 DIV. 
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Figure 3-24 Reduced rate of in vitro transcription in isolated nuclei of MECP2 -/y ES cell-derived 
neurons at 8 and 13 DIV but not at 3 DIV compared to wild-types. Equal numbers of nuclei at each age 
were incubated with unlabeled ATP, CTP, GTP and 1 µCi of [32P]-UTP for 0 and 30 minutes. The reaction 
was stopped by addition of TRIzol and total RNA was extracted. The amount of radioactivity incorporated 
in the total RNA was measured and standardized to the values obtained from wild-types (mean ± S.E.M, 
N=3, * P<0.05, **P<0.01 Student t-test) 
 
 
 
While at 3 days in vitro, MECP2-deficient neuronal nuclei are transcriptionally as active 
as the wild-type neuronal nuclei, at 8 and 13 DIV they are significantly less 
transcriptionally active compared to the wild-type nuclei (Figure 3.24). 
 
To assess if the reduced rate of in vitro transcription is solely due to the lack of MeCP2 
and not an ES cell line-specific behavior, I compared the rate of in vitro transcription in 
MECP2 Stop/y neurons, which have small nuclei as well, with the wild-type neurons. I 
found that the MECP2 Stop/y neuronal nuclei are also significantly less transcriptionally 
active compared to their aged match wild-type nuclei (Figure 3.25). 
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Figure 3-25 Reduced rate of in vitro transcription in isolated nuclei of MECP2 Stop/y ES cell-derived 
neurons compared with the wild-type nuclei. 0.168 million nuclei of wild-type and MECP2 Stop/y 
neurons at 8 DIV were incubated with 5 µCi [32P]-UTP for 0 and 30 minutes. The amount of radioactivity 
incorporated in the total RNA was then measured (mean ± S.E.M, N=3, *P<0.05, Student t-test) 
 
The possibility that MeCP2 may affect transcriptional activity of glial nuclei was also 
tested as I had found that the levels of MeCP2 in neurons and astrocytes are comparable 
(see Figure 3.19). Wild-type and MECP2 -/y astrocytic nuclei were similarly isolated and 
used for transcriptional analysis: nuclei of MeCP2-deficient astrocytes were 
transcriptionally as active as the nuclei of wild-type astrocytes (Figure 3.26) 
0 10 20 30 40
0
5000
10000
15000
20000
25000
Wild type
MECP2 -/y
Time (min)
co
un
ts
 p
er
 m
in
ut
e
 
 
Figure 3-26 The lack of MeCP2 does not affect the global rate of transcription in astrocytes. 0.29 
million nuclei of wild-type and MECP2 -/y astrocytes were incubated with 5 µCi [32P]-UTP for 0 and 45 
minutes. Radioactivity incorporated in the total RNA was then measured (mean ± S.E.M, N=3) 
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3.4. FTY720 increases BDNF levels and improves the 
symptoms in mice lacking MeCP2 
 
 
 
In view of what appears to be a global reduction of transcription rate of neuronal nuclei 
lacking MeCP2, the possibility was then tested that BDNF might be amongst the genes 
with affected transcription (see also Introduction). Regulation of BDNF expression was 
also attempted using an orally available compound currently in clinical trial. 
 
3.4.1. Reduced levels of BDNF in MECP2 -/y neurons 
 
Both mRNA and protein measurements showed a significant reduction in the expression 
of BDNF in 2-weeks-old cultures of MECP2 -/y ES cell-derived neurons as compared to 
the aged matched wild-type neurons (Figure 3.27). 
 
 
Figure 3-27 Reduced levels of BDNF expression in MeCP2-deficient neurons (A) Equal amount of 
protein lysates from 2-weeks-old cultures of wild-type and MECP2 -/y ES cell-derived neurons were 
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loaded in the SDS-gel and expression of BDNF and MeCP2 were assessed using immunoblotting. Tuj-1 
was used as loading control (B) Quantification of the Western blot in panel A shows a significant reduction 
in the BDNF expression (mean ± S.E.M, **P<0.01, Student t-test) (C) Reduced levels of BDNF expression 
in 2-weeks-old cultures of MECP2 -/y neurons compared to the wild-type neurons assessed by quantitative 
real-time RT-PCR (mean ± S.E.M, N=3, *P<0.05, Student t-test) 
 
 
 
 
3.4.2. Reduced levels of BDNF in various brain regions of MECP2 -/y mice 
 
 
Brains of wild-type and MECP2 -/y mice were dissected at 2 month of age and BDNF 
measurements performed using an ELISA protocol established in our laboratory 
(Kolbeck et al., 1999).  
 
In addition to the reported reduction of BDNF in the brain stem (Wang et al., 2006) and 
cerebellum (Chang et al., 2006), we found that the BDNF levels were also significantly 
reduced in hippocampus, striatum and the midbrain of the MECP2 knock-out mice but 
not in the olfactory bulbs, compared with those determined in wild-type littermates 
(Figure 3.28) 
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Figure 3-28 Reduced levels of BDNF in (A) hippocampus, (B) brain stem, (C) striatum, (E) 
cerebellum and (F) midbrain but not in the (D) olfactory bulbs of the MeCP2-deficient mouse brains. 
All the measurements have been done by ELISA on the brains of 2 months old mice (mean ± S.E.M, N=3) 
 
3.4.3. FTY720 increases BDNF expression in wild-type cortical neurons 
 
As it would be desirable to increase BDNF levels using small chemical compounds that 
could be administered orally in patients, the drug FTY720 was next tested. This drug is 
an analogue of sphinosine-1 phosphate (S1P) that diffuses through the blood-brain barrier 
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and is phosphorylated to its active moiety FTY720-P. While it is thought to primarily 
target cells of the immune system, FTY720 receptors are also expressed in microglia, 
oligodendrocytes, astrocytes and neurons. This drug may be used soon in the context of 
Multiple Sclerosis (MS) treatment and is advanced in clinical trials for this indication. 
 
Cortical neurons (14-18 DIV) were treated with FTY720-P (10 nM) for different periods 
of time (4 h, 8 h and 24 h) and BDNF levels analysed. A 2-fold increase of BDNF 
transcripts was observed after 4 h of FTY720-P stimulation. This increase was persistent 
after 8 h and 24 h of treatment (Fig. 3.29 A). Protein levels were also found to be 
increased by Western blot analysis (Fig. 3.29 B). FTY720-P was active only at a 
concentration range of 10 nM to 100 nM but not at 1 to 10 µM (Fig. 3.29 C-D), 
indicating a limited range of efficacies concentration. 
 
 
Figure 3-29 FTY720-P increases BDNF expression in wild-type neurons. (A) Quantitative real-time 
RT-PCR shows a significant increase in BDNF mRNA levels as early as 4 hours after treatment of the 
neuronal cultures with 10 nM FTY720-P (B) Western blot analysis on neuronal lysates treated with 
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FTY720-P also show a significant increase in BDNF at the protein levels (C) FTY720-P can stimulate 
BDNF expression in a concentration range of 10-100 nM as measured by quantitative real-time RT-PCR 
(D) At the protein levels also FTY720-P dependent increase of BDNF occurs in a range of 10-100 nM 
concentration (mean ± S.E.M, N=3, *P<0.05,** P<0.01, ***P<0.0001 Student t-test) 
 
 
3.4.4. FTY720 increases CREB phosphorylation by activating NMDA 
receptors and MAPK pathway 
 
As CREB phosphorylation is known to activate BDNF transcription (Greer and 
Greenberg, 2008), we next tested if FTY720-P treatment of neurons would cause the 
CREB phosphorylation. After 30min treatment with FTY720-P (50 nM), the levels of 
phospho-CREB (Ser133) were increased in primary cortical neurons (Figure 3.30 A). 
 
CREB can be activated through a variety of pathways in neurons including the MAPK 
pathway, activation Ca2+-Calmodulin-dependent protein kinases via increased levels of 
intracellular Ca2+ and the calcineurin pathway (Kingsbury et al., 2007). To test if any of 
these pathways could be involved in the FTY720-P-dependent BDNF transcription, the 
cultures were pre-treated for one hour with the MAPK inhibitor, U0126 (2 µM), the 
blocker of neuronal activity, TTX (10 µM), and the NMDA-receptors antagonist, APV 
(200 µM). The levels of both pMAPK1/2 (pERK1/2) and pCREB-Ser133 were increased 
after 30 minutes FTY720-P treatment. As readout, blockade of MAPK pathway by 
U0126 effectively blocked both ERK1/2 and CREB. Curiously, TTX and APV treatment 
also prevented FTY720-P-induced ERK1/2 and CREB phosphorylation (Figure 3.30 A). 
Both TTX and APV also blocked the increase in BDNF at protein levels mediated by 
FTY720-P (Figure3. 30 B-C).  
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Figure 3-30 Effect of FTY720-P on activation of ERK, CREB, and BDNF transcription. (A) 
Phosphorylation levels of CREB and ERK1/2 in cortical neuronal cultures (14 DIV) after 30 minutes of 
FTY720-P treatment either in control condition or in the presence of U0126, TTX or APV were determined 
by Western Blot (B) BDNF protein levels in primary cortical cultures (14 DIV) after 24 h treatment with 
FTY720-P (10 nM), in the presence of TTX (1 µM) or (C) APV (200 µM) were determined by Western 
blot 
 
 
 
These data then suggest that FTY720-P requires neuronal activity and activation of 
NMDA-receptors to mediate the activation of BDNF transcription mediated by CREB 
through Ca2+-dependent and MAPK pathways. 
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3.4.5. FTY720 increases BDNF expression in MECP2 deficient neurons and 
brains 
 
If drugs such as FTY720 are to be used to treat RTT patients, it is important to test 
whether or not FTY720 administration increases BDNF levels even in neurons lacking 
MeCP2.  
 
To answer this question, we treated the 3-weeks-old cultures of MECP2 -/y ES cell-
derived neuron with 10 nM FTY720-P and checked the BDNF expression both at mRNA 
and protein levels. Much like in the wild-type cortical neurons, FTY720-P induces the 
expression of the BDNF in MECP2-deficient neurons (Figure 3.31). 
 
Figure 3-31 FTY720-P induces BDNF expression in MeCP2 knock-out neurons. 
Cultures of MECP2 -/y ES cell-derived neurons (20 DIV) were treated with 10 nM FTY720-P for 4 hours 
and BDNF levels were measured (A) at the mRNA levels using quantitative real-time RT-PCR and (B) at 
the protein levels using Western blot analysis (mean ± S.E.M, N=3, *P<0.05, Student t-test) 
 
 
We next wondered if FTY720 would also increase the BDNF expression in vivo in the 
brains of MECP2 knock-out mice.  
 
Saline (0.9 % w/v NaCl in water) or FTY720 (0.1 mg/Kg body weight) was injected 
every 4 days intraperitoneally (IP) into MECP2 -/y mice from 4 weeks of age for a period 
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of 4 weeks. 24 hours after the last injection, mice were euthanized and brains were 
isolated and dissected to different regions for BDNF measurements. 
 
BDNF levels were increased significantly in the hippocampus and striatum of MECP2 
knock-out mice that have received the FTY720 compared to the control ones that had 
received saline (Figure 3.32) 
 
 
Figure 3-32 FTY720 administration in MECP2 -/y mice increased BDNF expression in some brain 
regions. IP injection of FTY720 (0.1 mg/Kg body weight every 4 days) led to a significant increase in the 
expression of BDNF in (A) hippocampus and (B) striatum of MECP2 -/y mice (mean ± S.E.M, N=3, 
*P<0.05, Student t-test) 
 
 
 
3.4.6. FTY720 improves the motor performance of MECP2 -/y mice 
 
 
During the course of injection of FTY720 in MECP2 knock-out mice for the BDNF 
measurement, we have noticed that the mutant mice receiving FTY720 were 
phenotypically less severely affected compared to the control mice receiving saline. For 
example, mice receiving FTY720 often did not show hind-limb clasping, a phenotype 
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that MECP2 mutant mice as well as BDNF mutant mice often show (Figure 3.33) (Guy et 
al., 2001, Rauskolb et al., 2010). 
 
Figure 3-33 FTY720 administration in MECP2 -/y mice attenuates the hind-limb clasping phenotype. 
An example of improvement of symptoms in MECP2 -/y mice receiving FTY720. (A) While 9-weeks-old 
control mouse shows hind-limb clasping (B) the MECP2 knock-out mice that received FTY720 (0.1 mg/Kg 
body weight every 4 days) for 3 weeks does not exhibit hind-limb clasping even at 11 weeks of age. 
 
The MECP2 knock-out mice as of 4 weeks of age start to become immobile and develop 
a stiff gait (Chen et al., 2001, Guy et al., 2001). To test whether the BDNF increase in the 
brain of MECP2 mutants may exacerbate locomotor dysfunction following FTY720 
injection, we performed a dark-cycle locomotor activity assay (running-wheel assay). As 
shown in Figure 3.34, the MECP2 -/y mice perform poorly in the running-wheel assay at 
6 to 7 weeks of age as compared to the wild-type littermates. 
 
Injections of mutant mice were started at 6 weeks of age and the recordings performed 
one week later for a period of 2 weeks (from 7 to 9 weeks of age). As shown in Figure 
3.34, FTY720 injection has moderately, but significantly, improved the motor 
performance of the MECP2 knock out mice. 
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Figure 3-34 FTY720 administration in MECP2 -/y mice improves the locomotor performance. Saline 
or FTY720 were IP injected in MECP2 -/y mice from 6 weeks of age and the performance in the running 
wheel assay was recorded for 2 weeks from 7 to 9 weeks of age. FTY720 injection led to a significant 
increase in the locomotor performance of the MECP2 -/y mice (mean ± S.E.M, N=3, ***P<0.001, Student 
t-test) 
 
3.4.7. FTY720 increases the lifespan of MECP2 -/y mice 
 
BDNF and MeCP2 have been previously proposed to be in the same pathway (Chang et 
al., 2006). Using mice under- or over-expressing BDNF compared with mice lacking 
MeCP2, it could be shown that the levels of BDNF negatively correlate with severity of 
the symptoms observed in mice lacking MeCP2 (Chang et al., 2006). we then injected 
FTY720 following the regime leading to increased BDNF levels in MECP2 -/y animals 
(see Figure 3.32), (0.1 mg/Kg body weight every 4 days). To exclude the severely 
affected mice we decided to start the injection as of 6 weeks of age (post-natal day 42) 
and record the lifespan. We found that FTY720 administration significantly increased the 
lifespan of Rett syndrome mice models from 68.7 days to 93.8 days (Figure 3.34) 
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Figure 3-35 FTY720 administration in MECP2 -/y mice improves the lifespan. MECP2 -/y mice 
receiving IP injection of FTY720 from P42 (week 6) live (93.8 days) significantly longer than mice 
receiving saline (68.7 days) (**P<0.01, Logrank tet) 
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4. Discussion 
 
 
 
The discovery that uniform populations of Pax6-positive radial glial cells can be 
generated from mouse ES cells (Bibel et al., 2007, Bibel et al., 2004) makes it now 
possible to explore early events of CNS development that have been previously difficult 
to examine in sufficient detail. These Pax-6-positive progenitors drop out of the cell cycle 
rapidly and differentiate simultaneously into essentially one cell type, namely 
glutamatergic neurons. This transition can thus be studied with accuracy which greatly 
facilitates the identification of phenotypes correlated with the absence of genes such as 
MECP2 (this study) as was also the case in a previous study with ES cells lacking Pax-6 
(Nikoletopoulou et al., 2007).  
 
 
4.1. Lack of MECP2 affects the proliferation of neuronal 
progenitors but not the ES cells 
 
 
During development, the most dramatic increase in brain volume occurs during the last 
three months of fetal life and the first two years after birth (Amiel-Tison et al., 2002). By 
the third year, the human brain has become about four times larger compared with its size 
at birth (Cox et al., 2006). Concomitantly, the skull follows the volumetric increase in the 
cerebral hemispheres, apparently by passive adaptation (Amiel-Tison et al., 2002). One 
early indicator of neurological impairment in Rett syndrome is the deceleration of head 
growth, leading to microcephaly (Chahrour and Zoghbi, 2007). Microcephaly is a 
condition in which the head remains significantly smaller than normal and it most often 
occurs as a result of a failure of brain development (Abuelo, 2007). The most frequent 
causes of microcephaly are mutations affecting the function of centromeres (Bond et al., 
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2005, Kumar et al., 2009, Thornton and Woods, 2009), though recently, mutations in the 
gene WDR62 were discovered in human causing microcephaly (Bilguvar et al., 2010). 
This gene seems to encode for a nuclear protein that is not associated with centromeres. 
In some RTT patients, microcephaly has been described as early as 3-4 months of age 
(Armstrong, 2001). Not only the RTT patients, but also the MECP2 mutant mice have 
small brains (Chen et al., 2001, Guy et al., 2001) and volumetric analyses of one-month-
old male brains showed a 25% reduction in whole brain volume compared to wild-types 
(Stearns et al., 2007). Precise morphometric measurements revealed a reduction in the 
volume of the cortex (11%), cerebellum (12%), amygdale (39%), hippocampus (21%), 
and striatum (29%) (Belichenko et al., 2008, Stearns et al., 2007). Recently, mutations in 
the FOXG1 gene have been identified in patients with the congenital variant of Rett 
syndrome (Ariani et al., 2008, Bahi-Buisson et al., 2010, Mencarelli et al., 2010). The 
Forkhead box G1 (FOXG1) is a transcription factor that is critical for forebrain 
development, where it promotes progenitor proliferation and suppresses premature 
neurogenesis (Bahi-Buisson et al., 2010, Dou et al., 1999, Shoichet et al., 2005). FOXG1 
and MECP2 are hypothesized to share a common molecular mechanism during neuronal 
development (Ariani et al., 2008). It has been postulated that microcephaly is a 
consequence of reduced neurogenesis, possibly as a result of an increased rate of 
apoptosis or reduced generation of neurons from progenitors (O'Driscoll and Jeggo, 
2008). While previous results indicate that cells expressing mutant form of MeCP2 have 
a growth disadvantage (Balmer et al., 2002, Maezawa et al., 2009, Young and Zoghbi, 
2004), there are still no published data indicating decreased proliferation of brain 
progenitors. 
 
A further complication in addressing this question in the developing human brain may 
result from the fact that MECP2 is an X-linked gene, with the possibility that the 
proportion of wild-type vs. mutant MeCP2 expressing cells in RTT brains may depend on 
the pattern of X chromosome inactivation. XCI is thought to be a random process, such 
that half of the cells have the maternal X chromosome active and the other half have the 
paternal X chromosome active. Although the majority of girls with classic RTT seem to 
have a random pattern of XCI in brain tissue (Shahbazian et al., 2002b), non-balanced 
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patterns have been observed in patients carrying mutant MECP2 (Renieri et al., 2003, 
Weaving et al., 2003) and in some cases may account for variability of phenotypic 
manifestations. In mice, the pattern of XCI seem to be frequently unbalanced in the brain 
of most MECP2 female heterozygote mutants, favouring expression of the wild-type 
allele (Young and Zoghbi, 2004). In this latter study, no MECP2 mutant female with a 
non-random XCI favouring expression of the mutant allele was detected. The brains of 
RTT patients showed no obvious degeneration, atrophy, inflammation, gliosis or 
neuronal migration defects (Jellinger et al., 1988, Reiss et al., 1993). It thus seems likely 
that wild-type neural progenitors have a growth advantage over MECP2 mutant 
progenitors which may explain the apparent non-random XCI in the brain of MECP2 
mutant mice and RTT patients. 
 
In single cell cloning of T lymphocytes from RTT patients, the MeCP2 mutant-
expressing clones were shown to be present at a significantly lower frequency than wild-
type clones (Balmer et al., 2002) suggesting that MeCP2 is not essential for lymphocyte 
growth but yet the lack of MeCP2 causes a growth disadvantage. Consistent with these 
data, it has recently been shown that MeCP2-deficient astrocytes grow substantially 
slower than wild-type astrocytes assessed by BrdU incorporation (Maezawa et al., 2009). 
However, none of these experiments directly addresses whether the lack of MeCP2 
affects the proliferation of neuronal progenitors or not.  
 
In my experiments, I could compare the rate of division of wild-type and MECP2 mutant 
cells at different stages of differentiation. The results showed that MeCP2-deficient ES 
cells proliferate similarly to wild-type ES cells (Figure 3.6), but that the neuronal 
progenitors lacking MeCP2 showed reduced BrdU incorporation (Figure 3.10). As a 
result, the MeCP2-deficient progenitors generated fewer neurons (Figure 3.8). 
Comparisons of the levels of MeCP2 expression revealed that MeCP2 is expressed at 
much lower levels in ES cell compared to neurons, about 150-folds less (Figure 3.7). 
Following retinoic acid treatment, used as trigger of neural commitment in our procedure, 
the levels of MeCP2 expression markedly increased (Figure 3.7). Thus, the low levels of 
MeCP2 expression in ES cells correlate with a lack of impact of MeCP2 absence in their 
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proliferation. As MeCP2-deficient progenitors clearly incorporate less BrdU than their 
wild-type counterparts, it would seem that MeCP2 only affects proliferation beyond a 
critical threshold of expression. However, my data do not exclude that the cellular 
context in which MeCP2 is expressed my also play a role. 
 
Both in human and in mouse, MeCP2 is expressed at detectable levels during brain 
development (week 26 in human brain, E11.5 in mouse telencephalon). However, its 
expression further increases with age (Shahbazian et al., 2002a). As a result, older 
neurons express higher levels of MeCP2 than young neurons and neuronal progenitors. 
This prompted the hypothesis that MeCP2 may not play an important role in the 
generation of neuronal progenitors and young neurons, but that it rather becomes 
important for the function of mature neurons (Shahbazian et al., 2002a). While I also 
observed an increased MeCP2 expression during the transition from neuronal progenitors 
into neurons (Figure 3.9) and even if the levels of MeCP2 expression were low in the 
progenitors its absence clearly caused a proliferation defect in the mutant cells. My in 
vitro data suggest then that the decreased proliferation observed with MeCP2-deficient 
neuronal progenitors may also contribute to the smaller brain size in mouse mutant and 
human. Current experiments are now addressing this question by comparing the 
developing brains of MECP2 -/y and wild-type embryos. 
 
 
 
4.2. MeCP2 regulates the size of neuronal nuclei 
 
 
Beyond the impact of MeCP2 on progenitors proliferation, a second new finding 
resulting from detailed observation of the differentiation of these progenitors is the lack, 
or strong delay, in the growth of nuclear diameter normally observed with wild-type 
neurons. In general, very little is known about the growth of nuclei during the course of 
neuronal differentiation. Indeed, the majority of studies on regulation of the nuclear size 
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have been performed on dividing cells. However, it was recently shown that synaptic 
activity induces dramatic changes in the geometry of the neuronal nuclei, but not in the 
nuclei of the astrocytes (Wittmann et al., 2009). Nuclear calcium signaling can 
dynamically alter the nuclear structure that in turn results in histone H3 phosphorylation. 
This observation provides a functional link between the geometry of neuronal nuclei and 
transcriptional regulation (Wittmann et al., 2009). Although it has been known for almost 
a decade that MECP2-deficient neurons in the brains of mutant mice have smaller nuclei 
(Chen et al., 2001), neither the regulation of nuclear size by MeCP2 nor the functional 
consequences of small nuclei for neurons have been investigated in any detail (see 
Results, 3.3).  
 
Presumably as a result of synchronous differentiation of progenitors in our ES cell-based 
system, I could readily follow the development of the neuronal nuclear size during the 
course of neuronal maturation in vitro. These experiments revealed a marked and rapid 
increase as neurons differentiate (Figure 3.11). In MECP2-deficient progenitors and 
neurons, the nuclear size was initially similar to wild-type neurons but it failed to 
increase with neuronal maturation. The increase in the nuclear size of the wild-type 
neurons is accompanied by a significant increase in the expression of MeCP2 (Figure 3.9). 
I also measured the nuclear size of neurons generated from 2 additional MECP2 mutant 
ES lines; MECP2 loxP/y and MECP2 Stop/y. Although the nuclei of MECP2 Stop/y 
neurons were initially (at DIV 3) of similar size compared to the wild-type neurons, they 
failed to grow with maturation similar to what I observed with the MECP2 -/y neurons. 
While nuclei of the MECP2 loxP/y neurons grew with maturation, they failed to enlarge 
to the same extent as wild-type nuclei (Figure 3.12 and Table 3.4). Western blot 
experiments indicated that the MECP2 loxP/y neurons expressed MeCP2 at around 40% 
of wild-type levels (Figure 3.5). This reduction is most likely a consequence of the 
neomycin selection cassette left in these cells (Guy et al., 2001). In line with this, Samaco 
and colleagues recently showed that the levels of MeCP2 were reduced by 40-50% in the 
brains of hypomorphic mice carrying this floxed allele. In addition, mice carrying this 
mutation show neurological symptoms and have a breathing problem (Samaco et al., 
2008). My results also confirmed that the insertion of the stop-cassette into MECP2 gene 
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in the MECP2 Stop/y neurons (Guy et al., 2007) efficiently prevents MeCP2 protein 
expression (Figure 3.5). In sum, these experiments indicate that the nuclear size of ES 
cell-derived neurons directly correlates with their levels of MeCP2 expression. 
 
To further exclude the possibility that the small nucleus phenotype is ultimately due to a 
“clonal effect”, a problem often seen with ES cells, MeCP2 was re-expressed in the very 
same cells displaying a small nuclei phenotype. In rescue experiments, MeCP2 was re-
expressed from its endogenous promoter in MECP2 Stop/y neurons. As expected, 
MeCP2 re-expression led to a rescue of the small nuclei phenotype (Figure 3.15). In line 
with this, acute expression of MeCP2 in MECP2-deficient neurons caused an 
enlargement of the nuclei (Figure 3.16). Therefore, the small nuclei phenotype is 
reversible if MeCP2 would be restored in the neuronal nuclei, a finding that fits with the 
reversibility of neurological symptoms observed in mice models or Rett syndrome (see 
Introduction) (Guy et al., 2007). Re-expression of MeCP2 was also found very recently 
to increase the cortical thickness of MECP2 Stop/y mice and to lead to enlargement of 
the brain (personal communication with Stuart Cobb, 11th Annual Rett Syndrome 
Symposium, Virginia, USA). 
 
I could also establish that the regulation of the neuronal nuclei size by MeCP2 is a cell-
autonomous phenotype. In the experiment in which MeCP2 was acutely expressed in the 
MECP2 -/y neurons, only the nuclei of the neurons over-expressing MeCP2 have 
enlarged but the nuclei of other neurons remained small (Figure 3.17), in line with recent 
in vivo experiment showing that MECP2 mutation results in cell-autonomous reduction in 
soma size of neurons in locus ceruleus (Taneja et al., 2009).  
 
Neuronal activity and subsequent calcium influx triggers the de novo phosphorylation of 
MeCP2 at serine 421 (S421) by a CaMKII-dependent mechanism. Moreover, MeCP2 
S421 phosphorylation is induced selectively in the brain in response to physiological 
stimuli and has been previously shown to control the ability of MeCP2 to regulate 
dendritic patterning, spine morphogenesis, and the activity-dependent induction of BDNF 
transcription (Zhou et al., 2006). Upon phosphorylation at S421, MeCP2 is thought to 
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bind less or less tightly to DNA in neuronal nuclei (Zhou et al., 2006). To test if this 
phosphorylation site would be required for the function of MeCP2 as a regulator of 
neuronal nuclei, I tested a MeCP2 S421A mutant and found that the small nuclei 
phenotype of MECP2 -/y neurons could also be rescued, just like with wild-type MeCP2 
(Figure 3.16). This is not surprising, but important as S421A is not a human Rett 
mutation and the MeCP2 S421A knock-in mice do not show any symptoms resembling 
the Rett syndrome mouse models (personal communication with Sonia Cohen, 11th 
Annual Rett Syndrome Symposium, Virginia, USA). 
 
In vivo, I observed a significant increase in the size of neuronal nuclei from the first week 
after birth (P7) to 7 months of age in CA3 area of hippocampus of wild-type mice (Figure 
3.22). This fits with my in vitro data that neuronal nuclei enlarge with maturation (Figure 
3.11). As wild-type dissociated cortical neurons, at 16 DIV express similar levels of 
MeCP2 compared to the wild-type ES cell-derived neurons at 8 DIV (Figure 3.14), I 
tested if the lack of MeCP2 in cortical neurons would also affect the nuclear size. These 
experiments revealed that the nuclei of cortical neurons lacking MeCP2 at 16 DIV were 
significantly smaller than wild-type neurons, as is the case in the CA3 area of 
hippocampus of 2 month old MECP2 -/y mice (Figure 3.23). This confirms the data 
obtained by the group of Rudolf Jaenisch showing smaller nuclear size in neurons in 
brains of MECP2-deficient mice (Chen et al., 2001, Giacometti et al., 2007, Luikenhuis 
et al., 2004).  
 
I next addressed the question of whether the nuclear size regulation by MeCP2 is specific 
to neurons. To this end, I isolated glial cells from the brains of wild-type and MECP2 
mutant mice and measured their nuclei in culture experiments. 
 
After immunostaining MeCP2 expression was evident in the nuclei of the wild-type 
astrocytes with a typical enrichment in the heterochromatin foci co-localized with 
Hoechst staining of DNA (Lewis et al., 1992). By contrast, in wild-type microglial cells 
no immunostaining of MeCP2 could be observed above background, i.e. MeCP2 staining 
in the nuclei of MECP2 -/y microglial cells (Figure 3.18). In the only publication 
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showing an immunostaining of MeCP2 in the nuclei of the wild-type microglia 
(Maezawa and Jin, 2010), the staining patter is not typical for MeCP2 but rather faint and 
diffuse unlike what is seen even in non-neural cells types such as rat liver fibroblasts 
(Lewis et al., 1992). While the wild-type microglial cells might express MeCP2, the 
expression levels are clearly much lower than those found in astrocytes. By contrast, 
wild-type astrocytes express significantly higher levels of MeCP2 than ES cell-derived 
neurons after 3 days, but similar to what is seen after 8 days in vitro in ES cell-derived 
neurons (Figure 3.19). In spite of this, the nuclear size of astrocytes lacking MeCP2 was 
not different from wild-type astrocytes, thus indicating that MeCP2 levels alone do not 
necessarily correlate with the size of nuclei in all cell types (Figures 3.20 & 3.21). In 
addition, the MeCP2-deficient astrocytes seem to divide at a similar rate compared with 
wild-type astrocytes as both cultures reached confluence similarly, once started with 
equal number of cells (data not shown). 
 
While Shahbazian and colleague initially reported that MeCP2 is absent in astrocytes 
(Shahbazian et al., 2002a), more recently several groups showed that astrocytes, 
microglia and oligodendrocytes express MeCP2 though at levels lower than neurons 
(Ballas et al., 2009, Maezawa and Jin, 2010, Maezawa et al., 2009). The conclusion 
drawn by Shahbazian and colleagues were based on the lack of detectable MeCP2 
immunoreactivity in astrocytes in contrast to neighboring neurons (Shahbazian et al., 
2002a) a result that can be explained by a lack of sensitivity to the relatively lower levels 
of MeCP2 in astrocytes compared with mature neurons in adult mouse brain. My results 
show that astrocytes express similar levels of MeCP2 to DIV 8 ES cell-derived neurons, 
and by comparison, to the DIV 16 cortical dissociated neurons (Figures 3.14 & 3.19). 
Skene and colleagues recently showed that the MeCP2 expression reaches its highest 
levels in mouse brain at around 5 weeks of age (Skene et al., 2010). Therefore, the level 
of MeCP2 in neurons in vitro might be far from the in vivo levels seen at maturation. 
Thus, differences in the age of the neurons used might underlie the apparent contradiction 
on MeCP2 expression in astrocytes vs. neurons, and a lack of sensitivity appears the 
likely explanation at this point. This is important, as glial cells were initially thought not 
to play any functional role in Rett syndrome as deletion of MECP2 only in post-mitotic 
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neurons was accepted to be sufficient to cause Rett-like phenotypes in mice (Chen et al., 
2001). However, it was recently shown that MeCP2 mutant glial cells are abnormal and 
are now hypothesized to somehow spread the consequences of MeCP2 deficiency 
through gap junctions (Ballas et al., 2009, Maezawa and Jin, 2010, Maezawa et al., 2009). 
Wild-type neurons cultured either on top of MECP2 -/y glia or treated with their 
conditioned medium had stunt dendrites (Ballas et al., 2009). This suggests MeCP2-
deficient glia have a non-cell autonomous effect on neuronal properties, probably as a 
result of aberrant secretion of unknown soluble factors. However, regardless of defects in 
MeCP2 mutant glial cells, my results suggest that the small nuclei phenotype is specific 
to the MeCP2-deficient neurons. Hence, it seems that it is not only the expression levels 
of MeCP2 in neurons that affect their nuclear size but rather a combination of MeCP2 
levels and other neurons specific factor(s), e.g. an interacting partner of MeCP2 that is 
expressed in neurons, but not in glial cell. Thus, it will be informative to compare the 
interacting partners of MeCP2 in pure neuronal (e.g. from the ES cell-derived neurons) vs. 
glial nuclei.  
 
As still very little is known about nuclear size regulation in cells of the nervous system, it 
is unclear if the size of nuclei changes in post-mitotic astrocytes in brain. My in vitro 
results clearly show that nuclei grow in post-mitotic neurons, and the astrocytes I cultured 
are still dividing. Note also that the neuronal nuclei in adult mice are far larger than after 
3 weeks in culture (compare Figures 3.11 and 3.22 for details). 
 
While the role of MeCP2 in the growth of neuronal nuclei has not been investigated in 
any details so far, another chromatin associated protein has been linked with nuclear size 
regulation: the linker histone H1 (Shen et al., 1995). It is one of the 5 histones (H1, H2A, 
H2B, H3 and H4), but unlike the other 4 family members, it is not part of the core 
histones. H1 binds to the linker DNA region (approximately 60 nucleotides in length) 
between the histone beads and seals off the nucleosome at the location at which the linker 
DNA enters and leaves the nucleosome. Since linker histones are rich in lysine and 
arginine (typically ~ 60 K+R per molecule residues in mammals) they neutralize the 
negative charge of the DNA at the linker region, helping stabilize the zig-zagged 30 nm 
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chromatin fiber and compact the chromatin (Woodcock et al., 2006). The loss of H1 in 
Tetrahymena results in an increase in nuclear size (Shen et al., 1995) consistent with an 
expansion of chromatin in response to an electrostatic imbalance (Woodcock et al., 2006). 
Interestingly, MeCP2 was shown to compete with linker histone H1 in binding to the 
linker DNA at the entry/exit site of nucleosome (Nikitina et al., 2007a). Recently, 
quantification of MeCP2 levels revealed that it is nearly as abundant as the histone 
octamer in the neuronal nuclei in adult (6-8 weeks) mouse brain (Skene et al., 2010) and 
MeCP2 deficiency was shown to result in global changes in neuronal chromatin structure, 
including elevated histone acetylation and a doubling of histone H1 levels. In MeCP2-
deficient neuronal nuclei, elevated H1 levels could in turn cause an enhanced compaction 
of the chromatin and a subsequent shrinkage of the nuclei (Shen et al., 1995, Woodcock 
et al., 2006). In MeCP2-deficient glial nuclei, on the other hand, neither histone 
acetylation nor H1 expression were changed (Skene et al., 2010). Moreover, the basal 
levels of linker histone H1 in glial nuclei are twice as much as in neurons in wild-type 
brains (Woodcock et al., 2006) which could also contribute to a different regulation of 
nuclear size by MeCP2 in these two cell types. It would then be interesting to test if the 
H1 levels are changed in the nuclei of MeCP2-deficient ES cell-derived neurons and if 
yes, to check whether re-expression of MeCP2, that rescues the small nuclei phenotype, 
would alter the H1 expression.  
 
The pattern of MeCP2 binding to DNA follows the pattern of the DNA methylation in 
vitro and in vivo (Skene et al., 2010). In other words, MeCP2 binds anywhere in the 
genome where the DNA is methylated both to the transcriptionally active and inactive 
genes (Yasui et al., 2007). However, the search for genes directly regulated by MeCP2 
has been surprisingly frustrating so far (Chahrour et al., 2008). The initial hypothesis that 
MeCP2 functions as a general repressor of transcription has been challenged as the 
transcriptional profiling of MECP2 mutant mice revealed down-, and not up-regulation of 
many genes, though at moderate levels (Chahrour et al., 2008). It is possible that MeCP2 
may have a more general role in neuronal nuclei than being just a transcriptional 
repressor. In the budding yeast Saccharomyces cerivisiae, blockade of cell growth by 
inhibition of TOR kinase leads to significant reduction of RNA Pol I activity (Mayer et 
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al., 2004) and of nucleolar (Tsang et al., 2003) and nuclear size (Jorgensen et al., 2007). 
While neurons are post-mitotic cells they are translationally exceptionally active 
compared with other cells. In fact, staining methods developed in the 19th century by 
Franz Nissl in particular stain neurons effectively not least because the dyes most 
frequently used are basic and stain nucleic acids. The so-called "Nissl granules" are 
ribosomes and the "Nissl substance" corresponds to the rough ER. It has also been shown 
that cerebral cortical nuclei are transcriptionally highly active compared to the nuclei 
from other cell types e.g. liver and glial nuclei (Thomas and Thompson, 1977, Thompson, 
1973) and the high rate of global transcription in cerebral cortical nuclei correlates with 
their large nuclear size. Given this background, I tested the possibility that MeCP2 
deficiency may cause a global change in the transcriptional activity of the neurons using a 
modified nuclear run-on assay (Thompson, 1973). Cell nuclei are isolated using gentle 
methods and incubated with unlabeled and radiolabled ribonucleotides (I used cold ATP, 
CTP, GTP and [32P]-UTP), total RNA is extracted and amount of radioactivity 
incorporated in the total RNA measured (Thompson, 1973). This simple approach allows 
changes in the rates of global transcription to be measured, which often differ from 
steady-state transcription levels assessed in microarrays. Although the method is time-
consuming and requires the use of radioactivity and large numbers of cells, it remains the 
most reliable, simple method to measure transcription rates directly. While 3 DIV 
MECP2 -/y ES cell-derived neurons were found to have a similar rate of in vitro 
transcription compared to their wild-type counterparts, the 8 DIV and 13 DIV MECP2 -/y 
ES cell-derived neuronal nuclei were significantly less transcriptionally active compared 
to their aged matched wild-type nuclei (Figure 3.24). This fits with previous data 
showing a strong correlation between nuclear size and RNA transcription levels (Sato et 
al., 1994, Schmidt and Schibler, 1995). In addition to the MECP2-/y neurons, the nuclei 
of MECP2 Stop/y neurons were significantly less transcriptionally active at 8 DIV 
compared to the wild-type nuclei (Figure 3.25). However, the overall rate of transcription 
was similar amongst nuclei of wild-type and MeCP2-deficient astrocytes (Figure 3.26). 
Thus, the lack of MeCP2 in neurons leads to the shrinking of nuclei that correlates with 
reduced rate of global transcription that is not detected in astrocytes, even though the 
levels of MeCP2 are comparable.  
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It is curious that the role of MeCP2 as a global regulator of transcription in neurons has 
not been unraveled before. However, previous studies used RNA isolated from the brain 
(Ben-Shachar et al., 2009, Chahrour et al., 2008, Tudor et al., 2002) and it is possible that 
cellular heterogeneity may have masked difference is levels of transcription . By contrast, 
I used a highly enriched neuronal population with very few glial cells. In addition, the 
methods routinely used for measuring gene expression, e.g. RT-PCR and microarrays, are 
designed to evaluate the steady-state mRNA levels which often differ from changes in 
transcription rates. Finally, most previous studies focused on the expression of mRNA 
and typically excluded rRNA. Around 97% of total RNA in eukaryotic cells are non-
coding RNAs e.g. transfer RNA (tRNA) and ribosomal RNA (rRNA) (Mattick and 
Gagen, 2001). Therefore, the difference in the global rate of transcription amongst wild-
type and MeCP2-deficient neurons is likely to be mostly due to non-coding RNAs rather 
than messenger RNAs (mRNAs). Recently, it was shown that methylation of human 
ribosomal gene promoter affects their expression (Ghoshal et al., 2004). Ribosomal 
RNAs are co-transcriptionally methylated (Zhang et al., 2009) and in the future, rate of 
rRNA biosynthesis could be directly measured in wild-type and mutant cell in a pulse-
labelling experiment using a methyl-group donator e.g. 3H-labeled L-methyl-methionine 
(Warner, 1991).  
 
The in vitro reversibility of the small nuclei phenotype leads to question whether this is 
just a structural reversibility or a functional reversibility as well. In other words, if 
restoration of MeCP2 enlarges the nuclei, does it also bring the global rate of 
transcription back to the normal levels? One way to answer this question would be to use 
the MECP2 Stop/y ES cell-derived neurons which have both small nuclei and low rate of 
transcription, re-express MeCP2 and then check the global rate of transcription.  
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4.3. FTY720 increases BDNF expression and improves the 
symptoms of mouse models of Rett syndrome 
 
 
In view of what appears to be a global reduction of transcription rate of neuronal nuclei 
lacking MeCP2, the possibility that BDNF might be amongst the genes with affected 
transcription was then tested in wild-type and mutant neurons derived from ES cells. 
BDNF is increasingly regarded as an endogenous neuroprotectant in the CNS (Tremblay 
et al., 1999) that also controls survival of cranial sensory neurons during development, 
and many aspects of synaptic function and plasticity throughout life (Bibel and Barde, 
2000). BDNF is expressed and secreted by many neurons in an activity-dependent 
manner throughout life (Balkowiec and Katz, 2000, Matsumoto et al., 2008). Both 
mRNA and protein measurement revealed a marked decrease in the expression of BDNF 
in the MECP2 -/y ES cell-derived neurons compared to the wild-type controls in 2 week 
old cultures (Figure 3.27), suggesting that this system could be used to begin to test 
substances for their ability to regulate BDNF levels, both in wild-type and in cell lacking 
MeCP2. 
 
 
The first studies to examine BDNF levels in cells lacking MeCP2 made use of cultured 
primary dissociated cortical neurons. Basal BDNF transcription levels were reported to be 
higher in the absence of MeCP2 consistent with the view that MeCP2 would repress 
transcription of genes such as BDNF (Chen et al., 2003, Martinowich et al., 2003). These 
results would predict that the MECP2 mutant brains should express higher levels of 
BDNF than wild-type brains. As it turns out, there is now agreement that MECP2 -/y 
mice actually exhibit less BDNF, both at the mRNA and protein levels (Chang et al., 
2006, Deng et al., 2007, Wang et al., 2006). These declines are not due to cell death but 
rather to decreased transcription. As BDNF levels are primarily regulated by excitatory 
input, it is possible, but still unclear, that reduced synaptic activity is primarily 
responsible for this decrease. Two weeks after birth, the levels of BDNF are similar in 
brains of MECP2 mutant mice compared with wild-type littermates (Chang et al., 2006), 
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but they fail to increase in the following weeks. Indeed, soon after birth, BDNF levels are 
quite low in most brain regions, but they increase by about 10-fold, presumably as a 
result of increased synaptic activity. This is thought to be relevant for the development of 
neuronal network, with BDNF being particularly significant for the development of 
GABA-ergic neurons (Hong et al., 2008, Rauskolb et al., 2010). BDNF protein levels 
were measured in various brain areas of the MECP2 -/y mice using an ELISA method, 
established a few years ago in our laboratory (Kolbeck et al., 1999). In the striatum, 
hippocampus, brain stem, cerebellum and midbrain but not in olfactory bulbs, the levels 
of BDNF were found to be  markedly reduced (Figure 3.28) compared to the values 
obtained from the wild-type littermates at 2 months of age. In this context, it is interesting 
to note that the BDNF conditional mutant mice and the MECP2 mutant mice exhibit 
similar phenotypes, e.g. smaller brain and hind-limp clasping (Chang et al., 2006, 
Rauskolb et al.). Curiously, in both cases only female mutants show obesity while the 
male mutant mice do not (Guy et al., 2001, Rauskolb et al., 2010). In addition, Chang 
and colleagues showed that levels of BDNF affect the disease progression in the MeCP2 
mutant mice. Thus, over-expression and down-regulation of BDNF in the forebrains 
improved or worsened the symptoms as well the life span of MeCP2 mutant mice, 
respectively (Chang et al., 2006). Respiratory abnormalities are also a common feature of 
Rett syndrome (Katz et al., 2009) and may contribute to up to 26% of deaths in RTT 
patient (Kerr et al., 1997). MeCP2 mutant mice also show respiratory abnormalities 
similar to the human RTT patients (Katz et al., 2009). Neural structures important for 
cardiorespiratory control, including the nodose cranial sensory ganglia and brainstem, 
exhibit very significant deficits in BDNF expression in the MECP2 null mouse brain 
(Wang et al., 2006).  
 
In view of these results, it would be desirable to attempt to increase BDNF levels using 
drugs affecting the transcription of the BDNF gene. This was first attempted using 
AMPAkine, CX546, a glutamate receptor agonist that mimics excitatory inputs 
(Nagarajan et al., 2001). Interestingly, treatment of MECP2 null mice with CX546 was 
shown to elevate nodose ganglia BDNF levels in vivo (Ogier et al., 2007). Moreover, 
AMPAkine treatment significantly improved the respiratory function in MECP2 null 
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mice, suggesting that compounds increasing BDNF levels may be of therapeutic value in 
RTT. However, AMPA agonists are too toxic to be used clinically in humans. With a 
similar idea in mind, our laboratory began to use FTY720 (fingolimod), an orally 
bioavailable compound that has shown efficacy in advanced clinical trials for the 
treatment of multiple sclerosis (MS) in Novartis (Chun and Hartung, 2010). FTY720 
crosses the blood-brain barrier and is phosphorylated in vivo to form FTY720-phosphate 
(FTY720-P), which resembles naturally occurring sphingosine-1 phosphate (S1P), an 
extracellular lipid mediator whose major effects are mediated by cognate G protein-
coupled receptors. There are at least five S1P receptor subtypes, known as S1P subtypes 
1-5 (S1P1-5), 4 of which bind FTY720-P (Sanchez and Hla, 2004). These receptors are 
expressed on a wide range of cells that are involved in many biological processes (Dev et 
al., 2008). S1P1 plays a key role in the immune system, regulating lymphocyte egress 
from lymphoid tissues into the circulation. FTY720-P initially activates lymphocyte S1P1 
via high-affinity receptor binding, yet, subsequently induces S1P1 down-regulation that 
prevents lymphocyte egress from lymphoid tissues, thereby reducing auto-aggressive 
lymphocyte infiltration into the central nervous system (Chun and Hartung). S1P 
receptors are also expressed by many CNS cell types and have been shown to influence 
cell proliferation, morphology, and migration (Dev et al., 2008).  
 
Interestingly, FTY720 also activates the MAP-kinase pathway (see below) suggesting 
then that it could potentially activate BDNF transcription. Experiments with primary 
cultures and ES cell-derived neurons both indicated that FTY720 increases BDNF levels, 
both at the mRNA and protein levels (Figures 3.29 & 3.31).  
 
With regard to the mode of action of FTY720, my experiments, in close collaboration 
with my colleague Dr. Rubén Deogracias, confirmed that FTY720 may indeed activate 
BDNF transcription by CREB phosphorylation following increased neuronal activity. 
Indeed, CREB (cAMP and Ca2+ regulated response element binding protein) is a major 
transcriptional regulator of the BDNF gene expression (Greer and Greenberg, 2008) and 
previous work indicated that FTY720-P stimulates MAPK activation in non-neuronal 
cells of the CNS (Osinde et al., 2007). We found that both CREB and ERK1/2 
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phosphorylation levels were elevated after 30 min of pFTY720 treatment of neuronal 
cultures (Figure 3.30 A). Increase in both BDNF expression and CREB and ERK1/2 
phosphorylation were abolished in the presence of MAPK inhibitor U0126 or Na+-
channel blocker tetrodotoxin (TTX) or the NMDA-receptor antagonist APV (Figure 3.30 
A). These results suggest a requirement for on-going neuronal activity for the effect of 
FTY720-P on activation of the MAPK-CREB signaling pathway and the subsequent 
increase in the BDNF expression. Based on these data, we propose the following model 
for effect of FTY720-P on the BDNF transcription. 
 
 
Figure 4-1 FTY720 increases BDNF transcription via activation of MAPK pathways. Based on our in 
vitro data, we suggest a model for effects of FTY720 on neurons. In this model, activation of S1P1 
receptors through FTY720 leads to calcium influx into neurons through NMDA receptors and causes 
ERK1/2 and CREB phosphorylation. Subsequently, BDNF transcription is increased.  
 
The FTY720-dependent increase in the BDNF expression observed in vitro prompted us 
to test whether increased BDNF levels can also be observed in vivo in brains of MeCP2-
deficient mice. However, if drugs such as FTY720 are to be used to treat RTT patients, it 
is important to test whether or not MeCP2 is required for FTY720-dependent increase in 
BDNF expression. We found that much like in the wild-type cortical neurons, FTY720-P 
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induces the expression of the BDNF in MeCP2-deficient ES cell-derived neurons both at 
mRNA and protein levels (Figure 3.31). 
 
Since we have observed that in vitro, high concentrations of FTY720 fail to increase 
BDNF expression (Figure 3.29), we chose a moderate concentration of FTY720 (0.1 
mg/Kg body weight) for injecting mutant mice at four-day intervals. The BDNF levels in 
the hippocampus and striatum of MECP2 null mice receiving FTY720 were significantly 
higher than the control mutant mice that only received saline (Figure 3.32). Stearns and 
colleagues observed a 29% reduction in the size of striatum of one-month-old MeCP2-
deficient male mice compared to their wild-type littermate (Stearns et al., 2007). The 
striatum is highly enriched in GABAergic neurons, mostly medium spiny neurons (> 
95%). In terms of growth and dendritic arborisation, unlike the glutamatergic neurons 
from CA1 area of hippocampus, the GABAergic neurons were shown to be greatly 
dependent on BDNF signalling (Rauskolb et al., 2010). Very recently, it was shown that 
mice in which MeCP2 was specifically deleted in GABAergic neurons, using the Viaat 
(Vesicular Inhibitory Amino Acid Transporter) driver of Cre, were post-natally lethal and 
showed a variety of symptoms ranging from seizure, ataxia, repetitive stereotypes, 
excessive grooming, reduced LTP and respiratory dysfunction (personal communication 
with Dr. Huda Zoghbi in 11th Annual Rett Syndrome Symposium, Virginia, USA). These 
mutant mice share many symptoms with the MeCP2 null mice. Thus, GABAergic 
neurons play an important role in the etiology of the Rett syndrome. Therefore, increased 
BDNF levels in the striatum of MeCP2 null mice upon FTY720 administration might be 
a significant element contributing to the improvement of the symptoms in these mice. 
Indeed, BDNF has long been known to be transported anterogradely from cortical 
afferent to the striatum, while little BDNF is locally produced in the striatum (Altar et al., 
1997, Baquet et al., 2004). BDNF deprivation of striatum could also explain the clasping 
phenotype observed both in MECP2 and BDNF mutant mice (Chang et al., 2006, Guy et 
al., 2001, Rauskolb et al., 2010). Anterograde deprivation of BDNF is also a common 
explanation for the symptoms seen in Huntington’s disease (Strand et al., 2007). 
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FTY720 administration improves the general conditions of MeCP2 mutant mice as well 
as their lifespan. During the course of injections, we noticed that the mutant mice 
receiving FTY720 were less symptomatic. For example, most of the MECP2 mutant mice 
receiving FTY720 either did not show hind-limb clasping or if yes, only at later ages (see 
Figure 33). As the death of MECP2 null mice is normally preceded with deterioration of 
the symptoms (Chen et al., 2001, Guy et al., 2001), we hypothesized that the attenuated 
symptoms in FTY720 injected MECP2 mutant mice might be accompanied with delay of 
death. Using the same regime of FTY720 injection that led to an increase in the BDNF 
expression (0.1 mg/Kg body weight every 4 days), starting at 6 weeks of age, we found 
that FTY720 injections led to a significant increase in the life span of the MECP2 null 
mice, compared to the saline injection (Figure 3.35). 
 
The MECP2 null mice develop a stiff gate as of 4-6 weeks of age and become extremely 
immobile (Chen et al., 2001, Guy et al., 2001). Shortly after, the body weight declines 
rapidly with obvious signs of dehydration. It is thought that the immobility would 
contribute to the weight loss and dehydration which eventually lead to the death (Chang 
et al., 2006). Therefore, we wondered if enhance locomotor activity would underlie at 
least partly the improved lifespan of MeCP2 mutant mice. To test this hypothesis we used 
a running wheel assay. At 6 weeks of age, the MECP2 null mice perform extremely 
poorly in this test. However, after 2 weeks of FTY720 injection, we observed a 
significant increase in the locomotor activity of the MECP2 null mice compared to the 
saline injected mutant mice. Interestingly, at the end of two weeks FTY720 injection, the 
MECP2 null mice had significantly higher locomotor activity than when the injection was 
started. This shows that FTY720 administration not only prevent the deterioration of the 
symptoms but also improves the locomotor activity of MeCP2 mutant mice possibly as a 
result of improved striatal function. 
 
Although a significant increase in BDNF expression is observed in the mutant mice that 
received FTY720, it cannot be concluded at this point that the symptom improvements 
can solely be accounted for by increased BDNF levels. In theory, FTY720 would have to 
be injected into BDNF and MECP2 double knock-out mice and symptom assessed. 
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However, this is a very difficult experiment that would necessitate the use of BDNF 
conditional knock-outs. Indeed, germ-line BDNF knock-out mice are born alive, but 
exhibit marked reduced growth and die before reaching the second postnatal week (Jones 
et al., 1994). Also, BDNF is known to be also expressed in peripheral tissues such as 
heart, lung and muscle, besides the CNS (Maisonpierre et al., 1990). Various BDNF 
conditional KO lines have been generated in various laboratories including ours 
(Rauskolb et al., 2010), but it is very difficult to predict at this point where exactly it 
would be important to delete BDNF to conclusively learn about its role in mediating the 
effects of FTY720. 
 
Also receptors for FTY720 are expressed not only in neurons but also in glial cells (Dev 
et al., 2008). While neurons principally express S1P1 and S1P3, microglia predominantly 
express S1P1 and astrocytes and oligodendrocytes mainly express S1P3 and S1P5, 
respectively (Aktas et al., 2010). As motioned before, MeCP2-deficient glia are abnormal 
and spread the MeCP2 deficiency through gap junction (Ballas et al., 2009, Maezawa and 
Jin, 2010, Maezawa et al., 2009) in a non-cell autonomous fashion, perhaps as a result of 
aberrant secretion of unknown soluble factors. In particular, it was shown that the MeCP2 
mutant microglia release 5 times more glutamate than wild-type microglia and damage 
dendrites and synapses (Maezawa and Jin, 2010). Therefore, FTY720 might also have 
some beneficial effects on the MeCP2 mutant glia and probably not all the symptom 
improvement observed are only due to an increased BDNF but rather combination of 
several factors including an increase in BDNF levels. 
 
Beyond FTY720, the in vitro differentiation system I used based on a comparison 
between wild-type and mutant ES cells suggests that it can provide novel insight into 
diseases of the nervous system. It can also be used to test drug candidates that may be 
improve the conditions of young children suffering from devastating diseases such as 
those caused by the lack of MeCP2. 
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